<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1702210525
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TALZENNA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TALAZOPARIB TOSYLATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        21112.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="EXCELLA GMBH CO. KG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            EXCELLA GMBH CO. KG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER INC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XX
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Talzenna is and how it works</strong></p><p>Talzenna contains the active substance talazoparib. It is a type of anticancer medicine known as a &lsquo;PARP (poly-ADP ribose polymerase) inhibitor&rsquo;.</p><p>&nbsp;</p><p>Patients with changes (mutations) in genes called BRCA are at risk of developing some forms of cancer. Talzenna works by blocking PARP, which is an enzyme that repairs damaged DNA in certain cancer cells. As a result, the cancer cells can no longer repair themselves and they die.</p><p>&nbsp;</p><p><strong>What Talzenna is used for</strong></p><p>Talzenna is used to treat adults with breast cancer of a type known as HER2-negative breast cancer who have an abnormal inherited BRCA gene.</p><p>&nbsp;</p><p>Talzenna is used in combination with a medicine called enzalutamide, to treat adults with prostate cancer with certain abnormal inherited or acquired genes called homologous recombination repair (HRR genes) and which no longer responds to a hormone therapy or surgical treatment to lower testosterone and has spread to other parts of the body (metastatic).</p><p>&nbsp;</p><p>Talzenna is used when the cancer has spread beyond the original tumour or to other parts of the body.&nbsp;</p><p>&nbsp;</p><p>Your healthcare provider will perform a test to make sure that Talzenna is right for you.</p><p>&nbsp;</p><p>If you have any questions about how Talzenna works or why this medicine has been prescribed for you, ask your doctor.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><em>&nbsp;</em></p><p><strong>Do not take Talzenna</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to talazoparib or any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are breast-feeding.</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor, pharmacist or nurse before taking Talzenna and during your treatment if you experience signs or symptoms described in this section.</p><p>&nbsp;</p><p><u>Low blood cell counts</u></p><p>Talzenna lowers your blood cell counts, such as your red blood cell count (anaemia), white blood cell count (neutropenia), or blood platelet count (thrombocytopenia). Signs and symptoms you need to look out for include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Anaemia:</strong> Being short of breath, feeling very tired, pale skin, or fast heartbeat &ndash; these may be signs of a low red blood cell count</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Neutropenia:</strong> Infection, developing chills or shivering, or fever &ndash; these may be signs of a low white blood cell count</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Thrombocytopenia:</strong> Bruising or bleeding for longer than usual if you hurt yourself &ndash; these may be signs of a low blood platelet count</p><p>&nbsp;</p><p>You will have regular blood tests during treatment with Talzenna to check your blood cells (white blood cells, red blood cells, and platelets).</p><p>&nbsp;</p><p><u>Serious problems with the bone marrow </u></p><p>Rarely, low blood cell counts may be a sign of more serious problems with the bone marrow such as myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML). Your doctor may want to test your bone marrow to check for these problems.</p><p>&nbsp;</p><p><u>Male and female contraception</u></p><p>Women who can become pregnant and men with partners who are or can become pregnant should use effective contraception.</p><p>Please see section &ldquo;Male and female contraception&rdquo; below.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Talzenna is not to be used in children or adolescents (under 18 years of age).</p><p>&nbsp;</p><p><strong>Other medicines and Talzenna</strong></p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription and herbal medicines. This is because Talzenna can affect the way some other medicines work. Also some medicines can affect the way Talzenna works.</p><p>&nbsp;</p><p>In particular, the following may increase the risk of side effects with Talzenna:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amiodarone, carvedilol, dronedarone, propafenone, quinidine, ranolazine and verapamil &ndash; generally used to treat heart problems.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clarithromycin and erythromycin antibiotics &ndash; used to treat bacterial infections.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itraconazole and ketoconazole &ndash; used to treat fungal infections.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cobicistat, darunavir, indinavir, lopinavir, ritonavir, saquinavir, telaprevir and tipranavir used to treat HIV infections/AIDS.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ciclosporin &ndash; used in organ transplantation to prevent rejection.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lapatinib &ndash; used to treat patients with certain types of breast cancer.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Curcumin (e.g. found in turmeric root) in some medicines (see also section Talzenna with food and drink below).</p><p>&nbsp;</p><p>The following medicines may reduce the effect of Talzenna:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carbamazepine and phenytoin &ndash; anti-epileptics used to treat seizures or fits.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s wort (<em>Hypericum perforatum</em>) &ndash; a herbal remedy used to treat mild depression and anxiety.</p><p>&nbsp;</p><p><strong>Talzenna with food and drink</strong></p><p>Do not use curcumin in food supplements while you are taking Talzenna as it may increase Talzenna&rsquo;s side effects. Curcumin is found in turmeric root and you should not use large amounts of turmeric root, but using spices in food is not likely to cause a problem.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy</strong></p><p>Talzenna could harm an unborn baby. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Your doctor will perform a pregnancy test prior to starting Talzenna.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should not use Talzenna if you are pregnant.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should not become pregnant while taking Talzenna.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Discuss contraception with your doctor if there is any possibility that you or your partner may become pregnant.</p><p>&nbsp;</p><p><strong>Male and female contraception</strong></p><p><strong>Women </strong>who are able to become pregnant should use effective birth control (contraception) during treatment with Talzenna and for at least 7 months after the last dose of Talzenna. Since the use of hormonal contraception is not recommended if you have breast cancer, you should use two non‑hormonal contraception methods.</p><p>Talk to your healthcare provider about birth control methods that may be right for you.</p><p>&nbsp;</p><p><strong>Men</strong> with female partners who are pregnant or able to become pregnant should use effective birth control (contraception), even after a vasectomy, during treatment with Talzenna and for at least 4&nbsp;months after the last dose.</p><p>&nbsp;</p><p><strong>Breast-feeding</strong></p><p>You should not breast-feed while taking Talzenna and for at least 1 month after the last dose. It is not known if Talzenna passes into breast milk.</p><p>&nbsp;</p><p><strong>Fertility</strong></p><p>Talazoparib may reduce fertility in men.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Talzenna may have a minor influence on the ability to drive and use machines. If you feel dizzy, weak, or tired (these are very common side effects of Talzenna), you should not drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>How much to take</strong></p><p>The recommended dose for breast cancer is one 1-mg capsule taken by mouth once daily.</p><p>The recommended dose for prostate cancer is one 0.5-mg capsule in combination with enzalutamide taken by mouth once daily. You should start or continue a gonadotropin-releasing hormone (GnRH) analog therapy during your treatment with TALZENNA and enzalutamide unless you have had a surgery to lower the amount of testosterone in your body (surgical castration).</p><p>&nbsp;</p><p>If you get certain side effects while you are taking Talzenna (see section 4), your doctor may lower your dose or stop treatment, either temporarily or permanently. The dose may be lowered to 0.75&nbsp;mg (taken as three 0.25-mg capsules) once daily, or 0.5&nbsp;mg (two 0.25-mg capsules) once daily, or 0.25&nbsp;mg (one 0.25-mg capsule) once daily.</p><p>&nbsp;</p><p>Swallow the capsule whole with a glass of water. Do not chew or crush the capsules. You can take Talzenna with food or between meals. Do not open the capsules. Contact with the capsule content should be avoided.</p><p>&nbsp;</p><p><strong>If you take more Talzenna than you should</strong></p><p>If you have taken more Talzenna than your normal dose, contact your doctor or nearest hospital right away. Urgent treatment may be necessary.</p><p>&nbsp;</p><p>Take the carton and this leaflet so that the doctor knows what you have been taking.</p><p><em>&nbsp;</em></p><p><strong>If you forget to take Talzenna</strong></p><p>If you miss a dose or vomit, take your next dose as scheduled. Do not take a double dose to make up for the forgotten or vomited capsules.</p><p>&nbsp;</p><p><strong>If you stop taking Talzenna</strong></p><p>Do not stop taking Talzenna unless your doctor tells you to.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist or nurse.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Tell your doctor straight away if you notice any of the following symptoms which could be a sign of serious blood disorder:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Very common</strong> (may affect more than 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Being short of breath, feeling very tired, having pale skin, or fast heartbeat &ndash; these may be signs of a low red blood cell count (anaemia).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infection, developing chills or shivering, or fever or feeling hot &ndash; these may be signs of a low white blood cell count (neutropenia).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bruising or bleeding for longer than usual if you hurt yourself &ndash; these may be signs of a low blood platelet count (thrombocytopenia).</p><p>&nbsp;</p><p><strong>Talk to your doctor if you get any other side effects. These can include:</strong></p><p><strong>&nbsp;</strong></p><p><strong>For </strong><strong>breast cancer:</strong></p><p>&nbsp;</p><p><strong>Very common</strong> (may affect more than 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low counts of white blood cells, red blood cells, and blood platelets</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling dizzy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick (nausea)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Being sick (vomiting)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in the abdomen</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss</p><p>&nbsp;</p><p><strong>Common</strong> (may affect up to 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alteration in taste (dysgeusia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Indigestion</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mouth inflammation</p><p><strong>&nbsp;</strong></p><p><strong>For prostate cancer:</strong></p><p><strong>&nbsp;</strong></p><p><strong>The most common side effects of TALZENNA when taken in combination with enzalutamide include:</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low red blood cell counts</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low white blood cell counts</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness or weakness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low platelet counts</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low calcium in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low sodium in the blood</p></td><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low phosphate in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bone injuries</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low magnesium in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased bilirubin in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low potassium in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in your sense of taste</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p><u>&nbsp;</u></p><p><u>To report any side effects:</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and the bottle or blister after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store below 30&deg;C.</p><p>After opening store TALZENNA below 30&deg;C and use it within 6 months</p><p>&nbsp;</p><p>Do not use this medicine if the pack is damaged or shows signs of tampering.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is talazoparib. Talzenna hard capsules come in different strengths.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talzenna 0.1&nbsp;mg hard capsules: each capsule contains talazoparib tosylate equivalent to 0.1&nbsp;mg talazoparib.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talzenna 0.25&nbsp;mg hard capsules: each capsule contains talazoparib tosylate equivalent to 0.25&nbsp;mg talazoparib.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talzenna 0.35&nbsp;mg hard capsules: each capsule contains talazoparib tosylate equivalent to 0.35&nbsp;mg talazoparib.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talzenna 0.5&nbsp;mg hard capsules: each capsule contains talazoparib tosylate equivalent to 0.5&nbsp;mg talazoparib.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talzenna 1&nbsp;mg hard capsules: each capsule contains talazoparib tosylate equivalent to 1&nbsp;mg talazoparib.</p><p>The other ingredients are:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Capsule content: silicified microcrystalline cellulose (sMCC) (microcrystalline cellulose and silicone dioxide).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.1&nbsp;mg capsule shell:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.25&nbsp;mg capsule shell: hypromellose (HPMC), yellow iron oxide (E172), and titanium dioxide (E171)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.35&nbsp;mg capsule shell:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.5&nbsp;mg capsule shell:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1&nbsp;mg capsule shell: hypromellose (HPMC), yellow iron oxide (E172), titanium dioxide (E171), and red iron oxide (E172)</p><p>&nbsp;</p><p>Printing ink: shellac (E904), propylene glycol (E1520), ammonium hydroxide (E527), black iron oxide (E172), and potassium hydroxide (E525).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Talzenna 0.1 mg is supplied as hard capsule with a white cap (printed with “Pfizer” in black) and a white body (printed with “TLZ 0.1” in black).
	
	Talzenna 0.25 mg is supplied as opaque, approximately 14.30 mm x 5.32 mm hard capsule with an ivory cap (printed with “Pfizer” in black) and a white body (printed with “TLZ 0.25” in black).
	
	Talzenna 0.35 mg is supplied as hard capsule with an ivory cap (printed with “Pfizer” in black) and an ivory body (printed with “TLZ 0.35” in black).
	
	Talzenna 0.5 mg is supplied as hard capsule with a light pink cap (printed with “Pfizer” in black) and a white body (printed with “TLZ 0.5” in black).
	
	Talzenna 1 mg is supplied as opaque, approximately 14.30 mm x 5.32 mm hard capsule with a light red cap (printed with “Pfizer” in black) and a white body (printed with “TLZ 1” in black).
	
	Talzenna 0.1 mg is available in plastic bottles of 30 hard capsules.
	
	Talzenna 0.25 mg is available in plastic bottles of 30 hard capsules.
	
	Talzenna 0.35 mg is available in plastic bottles of 30 hard capsules.
	
	Talzenna 0.5 mg is available in plastic bottles of 30 hard capsules.
	
	Talzenna 1 mg is available in plastic bottles of 30 hard capsules.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Pfizer Inc., USA</p><p>&nbsp;</p><p><strong>Manufactured By</strong></p><p>Excella GmbH &amp; Co. KG</p><p>Nuernberger Str. 12, Feucht, Bavaria, Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                December 2021 (EU) and June 2023 (US)
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو تالزينا وما هي طريقه عمله</strong></p><p dir="RTL">يحتوي تالزينا على المادة الفعالة تالازوباريب. وهي نوع من أنواع الأدوية المضادة للسرطان التي تُعرف باسم &quot;مثبطات إنزيمات PARP (البوليميراز متعدد ريبوز الأدينوسين ثنائي الفوسفات (ADP))&quot;.</p><p>&nbsp;</p><p dir="RTL">&nbsp;إن المرضى الذين لديهم تغيرات (طفرات) في جينات تُعرف باسم جينات سرطان الثدي (BRCA)، معرضون لخطر الإصابة ببعض أشكال السرطان. يعمل تالزينا عن طريق حصر إنزيم البوليميراز متعدد ريبوز الأدينوسين ثنائي الفوسفات، وهو إنزيم يقوم بإصلاح الحمض النووي (DNA) التالف في بعض الخلايا السرطانية. ونتيجة لذلك، تصبح الخلايا السرطانية غير قادرة على إصلاح نفسها وتموت.</p><p>&nbsp;</p><p dir="RTL"><strong>ما هي دواعي استعمال تالزينا</strong></p><p dir="RTL">يُستخدم تالزينا لعلاج البالغين المصابين بسرطان الثدي من نوع يُعرف باسم سرطان الثدي السلبي لمستقبلات عامل النمو البشري الثاني (HER2)، وجين سرطان الثدي الموروث لديهم غير طبيعي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم تالزينا مع دواء يُسمى إنزالوتاميد لعلاج البالغين المصابين بسرطان البروستاتا الذين لديهم بعض الجينات غير الطبيعية الموروثة أو المكتسبة التي تُسمى إصلاح إعادة التركيب المتماثل (جينات HRR) والتي لم تعد تستجيب للعلاج الهرموني أو العلاج الجراحي لخفض هرمون التستوستيرون وانتشرت إلى أجزاء أخرى من الجسم (نقيلي).</p><p>&nbsp;</p><p dir="RTL">&nbsp;يُستخدم تالزينا عندما ينتشر السرطان إلى خارج موضع الورم الأصلي، أو إلى أجزاء أخرى من الجسم.&nbsp;</p><p>&nbsp;</p><p dir="RTL">سيُجري مقدم رعايتك الصحية اختبار للتأكد من أن تالزينا مناسب لك.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة حول كيفية عمل تالزينا أو سبب وصف هذا الدواء لك، فاسأل طبيبك.</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع الاستعمال</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه تالازوباريب أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم ٦).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ ترضعين رضاعة طبيعية.</p><p>&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند الاستعمال</strong></p><p dir="RTL">&nbsp;تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل تناول تالزينا وخلال فترة علاجك إذا ظهرت عليك علامات أو أعراض موضحة في هذا القسم.</p><p>&nbsp;</p><p dir="RTL"><u>انخفاض تعداد خلايا الدم البيضاء</u></p><p dir="RTL">يقلل تالزينا من تعداد خلايا الدم لديك، مثل تعداد خلايا الدم الحمراء (فقر الدم)، أو تعداد خلايا الدم البيضاء (قلة العدلات)، أو تعداد الصفائح الدموية (قلة الصفيحات). تتضمن العلامات والأعراض التي تحتاج إلى الانتباه تحسبًا لظهورها ما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>فقر الدم:</strong> الشعور بضيق التنفس، أو الشعور بالتعب الشديد، أو شحوب الجلد، أو تسارع نبضات القلب &ndash; قد تكون هذه علامات على انخفاض تعداد خلايا الدم الحمراء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قلة العدلات:</strong> الإصابة بالعدوى، أو القشعريرة، أو الارتجاف، أو الحمى &ndash; قد تكون هذه علامات على انخفاض تعداد خلايا الدم البيضاء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قلة الصفيحات:</strong> التكدم أو النزيف لفترة أطول من المعتاد إذا جرحت نفسك &ndash; قد تكون هذه علامات على انخفاض تعداد الصفائح الدموية</p><p>&nbsp;</p><p dir="RTL">ستخضع لفحوصات دم منتظمة خلال فترة العلاج باستخدام تالزينا لفحص خلايا الدم لديك (خلايا الدم البيضاء، وخلايا الدم الحمراء، والصفائح الدموية).</p><p>&nbsp;</p><p dir="RTL"><u>مشكلات خطيرة في نخاع العظم</u></p><p dir="RTL">&nbsp;نادرًا ما قد يكون الانخفاض في تعداد خلايا الدم علامة على مشكلات أخطر في نخاع العظم، مثل متلازمة خلل التنسج النقوي (MDS) أو ابيضاض الدم النقوي الحاد (AML). وقد يرغب طبيبك في اختبار نخاع العظم لديك بحثًا عن هذه المشكلات.</p><p>&nbsp;</p><p dir="RTL"><u>وسائل منع الحمل للذكور والإناث</u></p><p dir="RTL">ينبغي أن تستخدم كل من السيدات القادرات على الإنجاب والرجال المتزوجين من سيدات حوامل أو قادرات على الإنجاب وسائل فعالة لمنع الحمل.</p><p dir="RTL">&nbsp;يُرجى الاطلاع على قسم &quot;وسائل منع الحمل للذكور والإناث&quot; أدناه.</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">إن تالزينا غير مخصص للاستخدام مع الأطفال أو المراهقين (الذين تقل أعمارهم عن ١٨ عامًا).</p><p>&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية.</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرضة إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى. يتضمن هذا الأدوية التي يتم الحصول عليها دون وصفة طبية والأدوية العشبية. وذلك نظرًا لأن تالزينا يمكن أن يؤثر على طريقة عمل بعض الأدوية الأخرى. قد تؤثر بعض الأدوية أيضًا على طريقة عمل تالزينا.</p><p>&nbsp;</p><p dir="RTL">على وجه الخصوص، قد تزيد الأدوية التالية من خطر الآثار الجانبية عند استخدامها بالتزامن مع تالزينا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أميودارون، وكارفيديلول، ودرونيدارون، وبروبافينون، وكينيدين، ورانولازين، وفيراباميل &ndash; تُستخدم عادةً لعلاج المشكلات القلبية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضادان الحيويان كلاريثروميسين وإريثرومايسين &ndash; يُستخدمان لعلاج حالات العدوى البكتيرية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيتراكونازول وكيتوكونازول &ndash; يُستخدمان لعلاج حالات العدوى الفطرية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كوبيسيستات، ودارونافير، وإندينافير، ولوبينافير، وريتونافير، وساكوينافير، وتيلابريفير، وتيبرانافير، وهي أدوية تُستخدم لعلاج عدوى فيروس نقص المناعة البشرية (HIV)/الإيدز.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين &ndash; يُستخدم في زراعة الأعضاء لمنع رفض الجسم للأعضاء المزروعة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لاباتينيب &ndash; يُستخدم لعلاج المرضى المصابين بأنواع معينة من سرطان الثدي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكركمين (على سبيل المثال، الموجود في جذور الكركم) في بعض الأدوية (انظر أيضًا قسم تالزينا مع الطعام والشراب أدناه).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تؤدي الأدوية التالية إلى تقليل فعالية تالزينا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاربامازيبين وفينيتوين &ndash; هما من مضادات الصرع ويُستخدمان لعلاج النوبات أو التشنجات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عشبة سانت جون (هايبريكوم بيرفوراتوم) &ndash; علاج عشبي يُستخدم لعلاج الاكتئاب والقلق الخفيفين.</p><p>&nbsp;</p><p dir="RTL"><strong>تناول تالزينا مع الطعام والشراب</strong></p><p dir="RTL">لا تستخدم الكركمين في المكملات الغذائية خلال فترة تناول تالزينا، لأنه قد يزيد من الآثار الجانبية لتالزينا. يوجد الكركمين في جذور الكركم، وينبغي لك عدم استخدام كميات كبيرة من جذور الكركم، ولكن من المستبعد أن يسبب استخدام التوابل في الطعام مشكلة.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">قد يُلحق تالزينا الضرر بالجنين. إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ ربما تكونين حاملًا، أو تخططين للإنجاب، فاستشيري طبيبكِ أو الصيدلي قبل تناول هذا الدواء. سيُجري طبيبكِ اختبار حمل لكِ قبل البدء في تناول تالزينا.</p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي ألا تستخدمي تالزينا إذا كنتِ حاملًا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي ألا تحملي خلال فترة تناول تالزينا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ناقشي مع طبيبكِ استخدام وسائل منع الحمل إذا كانت هناك أي إمكانية لأن تحملي، أو لأن تحمل زوجتك.</p><p>&nbsp;</p><p dir="RTL"><strong>وسائل منع الحمل للذكور والإناث</strong></p><p dir="RTL"><strong>السيدات</strong> القادرات على الإنجاب ينبغي أن يستخدمن وسيلة فعالة لتحديد النسل (منع الحمل) خلال فترة العلاج بتالزينا ولمدة ٧ أشهر على الأقل بعد تلقي الجرعة الأخيرة من تالزينا. وبما أنه لا يوصى باستخدام وسائل منع الحمل الهرمونية إذا كنتِ مصابة بسرطان الثدي، فينبغي لكِ استخدام وسيلتين من وسائل منع الحمل غير الهرمونية.</p><p dir="RTL">تحدثي إلى مقدم رعايتكِ الصحية بشأن وسائل تحديد النسل التي يمكن أن تكون مناسبة لكِ.</p><p>&nbsp;</p><p dir="RTL"><strong>الرجال</strong> المتزوجون من سيدات حوامل أو قادرات على الإنجاب ينبغي أن يستخدموا وسيلة فعالة لتحديد النسل (منع الحمل)، حتى بعد الخضوع لعملية استئصال الأسهر، خلال فترة العلاج بتالزينا ولمدة ٤ أشهر على الأقل بعد تلقي الجرعة الأخيرة منه.</p><p>&nbsp;</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">ينبغي لكِ ألا ترضعي رضاعة طبيعية خلال فترة تناول تالزينا ولمدة شهر واحد على الأقل بعد تلقي الجرعة الأخيرة منه. لا يُعرف ما إذا كان تالزينا يُفرَز في حليب الأم أم لا.</p><p>&nbsp;</p><p dir="RTL"><strong>الخصوبة</strong></p><p dir="RTL">قد يقلل تالازوباريب الخصوبة لدى الرجال.</p><p>&nbsp;</p><p dir="RTL"><strong>تأثير تالزينا على القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يكون لتالزينا تأثير بسيط على قدرتك على القيادة واستخدام الآلات. فإذا شعرت بالدوار أو الضعف أو التعب (هذه آثار جانبية شائعة جدًا لتالزينا)، ينبغي ألا تقود أو تستخدم الآلات.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا مثلما أخبرك طبيبك أو الصيدلي. وارجع إلى طبيبك أو الصيدلي إذا لم تكن متأكدًا مما ينبغي لك فعله.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;الكمية التي ينبغي تناولها</strong></p><p dir="RTL">الجرعة الموصى بها هي تناول كبسولة تركيز ١ ملجم عن طريق الفم مرة واحدة يوميًا.</p><p dir="RTL">الجرعة الموصى بها لسرطان البروستاتا هي كبسولة واحدة ٠,٥ ملجم مع إنزالوتاميد عن طريق الفم مرة واحدة يوميًا. يجب أن تبدأ أو تستمر في العلاج التناظري للهرمون المطلق لموجهة الغدد التناسلية (GnRH) أثناء علاجك باستخدام تالزينا وإنزالوتاميد، ما لم تكن قد خضعت لعملية جراحية لخفض كمية هرمون التستوستيرون في جسمك (الإخصاء الجراحي).</p><p>&nbsp;</p><p dir="RTL">إذا أُصبت بآثار جانبية معينة خلال فترة تناول تالزينا (انظر القسم ٤)، فيمكن أن يقلل طبيبك جرعتك أو يوقف العلاج، إما بصفة مؤقتة أو دائمة. يمكن تقليل الجرعة إلى ٠,٧٥ ملجم (يتم تناولها على ثلاث كبسولات بتركيز ٠,٢٥ ملجم) مرة واحدة يوميًا، أو ٠,٥ ملجم (كبسولتان بتركيز ٠,٢٥ ملجم) مرة واحدة يوميًا، أو ٠,٢٥ ملجم (كبسولة واحدة بتركيز ٠,٢٥ ملجم) مرة واحدة يوميًا.</p><p>&nbsp;</p><p dir="RTL">ابتلع الكبسولة كاملةً مع كوب من الماء. لا تمضغ الكبسولات أو تسحقها. يمكنك تناول تالزينا مع الطعام أو بين الوجبات. لا تفتح الكبسولات. ينبغي تجنب ملامسة محتويات الكبسولة.</p><p>&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من تالزينا</strong></p><p dir="RTL">إذا تناولت جرعة أكبر من الجرعة المعتادة من تالزينا، فاتصل بطبيبك أو المستشفى الأقرب لك على الفور. فقد يلزم تلقي العلاج العاجل.</p><p>&nbsp;</p><p dir="RTL">خذ العبوة الكرتونية وهذه النشرة معك حتى يعلم الطبيب ما تناولته.</p><p><em>&nbsp;</em></p><p dir="RTL"><strong>نسيان تناول جرعة تالزينا</strong></p><p dir="RTL">إذا فاتتك إحدى الجرعات أو تقيأت، فتناول جرعتك التالية حسب الجدول. لا تتناول جرعة مضاعفة لتعويض الكبسولات التي نسيت تناولها أو تقيأتها.</p><p>&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول تالزينا</strong></p><p dir="RTL">لا تتوقف عن تناول تالزينا إلا إذا أخبرك طبيبك بذلك.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى حول استخدام هذا الدواء، فاطرحها على طبيبك أو الصيدلي أو الممرضة.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، غير أنها لا تصيب الجميع.</p><p>&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك على الفور إذا لاحظت أيًا من الأعراض التالية التي يمكن أن تكون علامة على اضطراب خطير في الدم:</strong></p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;شائعة جدًا</strong> (قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بضيق التنفس، أو الشعور بالتعب الشديد، أو شحوب الجلد، أو تسارع نبضات القلب &ndash; قد تكون هذه علامات على انخفاض تعداد خلايا الدم الحمراء (فقر الدم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بالعدوى، أو القشعريرة، أو الارتجاف، أو الحمى، أو الشعور بارتفاع حرارة الجسم &ndash; قد تكون هذه علامات على انخفاض تعداد خلايا الدم البيضاء (قلة العدلات).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التكدم أو النزيف لفترة أطول من المعتاد إذا جرحت نفسك &ndash; قد تكون هذه علامات على انخفاض تعداد الصفائح الدموية (قلة الصفيحات).</p><p>&nbsp;</p><p dir="RTL"><strong>تحدث إلى طبيبك إذا أصبت بأي آثار جانبية أخرى. يمكن أن تتضمن هذه الآثار:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>في ما يتعلق بسرطان الثدي:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا </strong>(قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض تعداد خلايا الدم البيضاء، وخلايا الدم الحمراء، والصفائح الدموية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;انخفاض الشهية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور برغبة في التقيؤ (الغثيان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التقيؤ (القيء)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠ أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في حاسة التذوق (خلل الذوق)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر الهضم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الفم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في ما يتعلق بسرطان البروستاتا:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تشمل الآثار الجانبية الأكثر شيوعًا لتالزينا عند تناوله مع إنزالوتاميد ما يأتي:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض تعداد خلايا الدم الحمراء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض تعداد خلايا الدم البيضاء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب أو الضعف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض تعداد الصفائح الدموية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نسبة الكالسيوم في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالغثيان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الشهية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نسبة الصوديوم في الدم</p></td><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نسبة الفوسفات في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إصابات العظام</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نسبة المغنيسيوم في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة نسبة البيليروبين في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نسبة البوتاسيوم في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغييرات في حاسة التذوق لديك</p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا أُصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. ويتضمن ذلك أي آثار جانبية محتملة غير مذكورة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p><u>&nbsp;</u></p><p dir="RTL"><u>للإبلاغ عن أي آثار جانبية:</u></p><p>&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ والسلامة الدوائية (NPC)</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>مركز الاتصال بالهيئة العامة للغذاء والدواء (SFDA): ۱۹۹۹۹</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>الموقع الإلكتروني: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>&nbsp;<strong>الدول الأخرى في مجلس التعاون لدول الخليج العربية (</strong>GCC<strong>)</strong></p><p><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">يُرجى الاتصال بالهيئات المختصة المعنية.</p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المُدون على العبوة الكرتونية والزجاجة أو شريط البليستر بعد الرمز &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p>&nbsp;</p><p dir="RTL">خزن الدواء في درجة حرارة أقل من ٣٠ درجة مئوية.</p><p dir="RTL">بعد الفتح، خزن تالزينا في درجة حرارة أقل من ٣٠ درجة مئوية واستخدمه خلال ٦ أشهر</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء إذا كانت العبوة تالفة أو تظهر عليها علامات عبث.</p><p>&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير على حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي تالازوباريب. تتوفر كبسولات تالزينا الصلبة بتركيزين مختلفين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبسولات تالزينا الصلبة ٠,١ ملجم: تحتوي كل كبسولة على تالازوباريب توزيلات بما يعادل ٠,١ ملجم من تالازوباريب.</p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>كبسولات تالزينا الصلبة ٠,٢٥ ملجم: تحتوي كل كبسولة على تالازوباريب توزيلات بما يعادل ٠,٢٥ ملجم من تالازوباريب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبسولات تالزينا الصلبة ٠,٣٥ ملجم: تحتوي كل كبسولة على تالازوباريب توزيلات بما يعادل ٠,٣٥ ملجم من تالازوباريب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبسولات تالزينا الصلبة ٠,٥ ملجم: تحتوي كل كبسولة على تالازوباريب توزيلات بما يعادل ٠,٥ ملجم من تالازوباريب.</p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>كبسولات تالزينا الصلبة ١ ملجم: تحتوي كل كبسولة على تالازوباريب توزيلات بما يعادل ١ ملجم من تالازوباريب.</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; محويات الكبسولة: سليولوز بلوري مكروي مضاف إليه سيليكا (sMCC) (سليولوز بلوري مكروي وثاني أكسيد السيليكون).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غلاف الكبسولة تركيز ٠,١ ملجم:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غلاف الكبسولة تركيز ٠,٢٥ ملجم: هيبروميلوز (HPMC)، وأكسيد الحديد الأصفر (E172)، وثاني أكسيد التيتانيوم (E171)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غلاف الكبسولة تركيز ٠,٣٥ ملجم:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غلاف الكبسولة تركيز ٠,٥ ملجم:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غلاف الكبسولة تركيز ١ ملجم: هيبروميلوز (HPMC)، وأكسيد الحديد الأصفر (E172)، وثاني أكسيد التيتانيوم (E171)، وأكسيد الحديد الأحمر (E172)</p><p>&nbsp;</p><p dir="RTL">حبر الطباعة: الشيلاك ((E904)، وبروبيلين جليكول ((E1520، وهيدروكسيد الأمونيوم ((E527، وأكسيد الحديد الأسود ((E172، وهيدروكسيد البوتاسيوم (E525).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوفر تالزينا ٠,١ ملجم في شكل كبسولة صلبة لها غطاء أبيض (مطبوع عليه كلمة &quot;Pfizer&quot; باللون الأسود) وجسم أبيض اللون (مطبوع عليه &quot;TLZ 0.1&quot; باللون الأسود).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر تالزينا ٠,٢٥ ملجم في شكل كبسولة صلبة غير شفافة مقاسها ١٤,٣٠ ملليمترًا &times; ٥,٣٢ ملليمترات تقريبًا ولها غطاء بلون العاج (مطبوع عليه كلمة &quot;Pfizer&quot; باللون الأسود) وجسم أبيض اللون (مطبوع عليه &quot;TLZ 0.25&quot; باللون الأسود).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر تالزينا ٠,٣٥ ملجم في شكل كبسولة صلبة لها غطاء بلون العاج (مطبوع عليه كلمة &quot;Pfizer&quot; باللون الأسود) وجسم عاجي اللون (مطبوع عليه &quot;TLZ 0.35&quot; باللون الأسود).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر تالزينا ٠,٥ ملجم في شكل كبسولة صلبة لها غطاء بلون وردي فاتح (مطبوع عليه كلمة &quot;Pfizer&quot; باللون الأسود) وجسم أبيض اللون (مطبوع عليه &quot;TLZ 0.5&quot; باللون الأسود).</p><p>&nbsp;</p><p dir="RTL">يتوفر تالزينا ١ ملجم في شكل كبسولة صلبة غير شفافة مقاسها ١٤,٣٠ ملليمترً &times; ٥,٣٢ ملليمترات تقريبًا ولها غطاء لونه أحمر فاتح (مطبوع عليه كلمة &quot;Pfizer&quot; باللون الأسود) وجسم أبيض اللون (مطبوع عليه &quot;TLZ 1&quot; باللون الأسود).</p><p>&nbsp;</p><p dir="RTL">يتوفر تالزينا ٠,١ ملجم في زجاجات بلاستيكية تحتوي على ٣٠ كبسولة صلبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر تالزينا ٠,٢٥ ملجم في زجاجات بلاستيكية تحتوي على ٣٠ كبسولة صلبة.</p><p>&nbsp;</p><p dir="RTL">يتوفر تالزينا ٠,٣٥ ملجم في زجاجات بلاستيكية تحتوي على ٣٠ كبسولة صلبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر تالزينا ٠,٥ ملجم في زجاجات بلاستيكية تحتوي على ٣٠ كبسولة صلبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر تالزينا ١ ملجم في زجاجات بلاستيكية تحتوي على ٣٠ كبسولة صلبة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">Pfizer Inc., USA، الولايات المتحدة الأمريكية</p><p>&nbsp;</p><p dir="RTL"><strong>&rlm;الشركة</strong> <strong>المصنعة</strong></p><p dir="RTL">Excella GmbH &amp; Co. KG</p><p dir="RTL">Nuernberger Str. &lrm;12, Feucht, Bavaria, Germany، ألمانيا</p><p dir="RTL"><u>&nbsp;</u></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ديسمبر ٢٠٢١ و يونيو ۲۰۲۳ (الولايات المتحدة).
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Talzenna 0.1 mg hard capsules 
Talzenna 0.25 mg hard capsules 
Talzenna 0.35 mg hard capsules 
Talzenna 0.5 mg hard capsules 
Talzenna 1 mg hard capsules


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                TALZENNA 0.1 mg hard capsules
Each hard capsule contains talazoparib tosylate equivalent to 0.1 mg talazoparib.

Talzenna 0.25 mg hard capsules
Each hard capsule contains talazoparib tosylate equivalent to 0.25 mg talazoparib.

Talzenna 0.35 mg hard capsules
Each hard capsule contains talazoparib tosylate equivalent to 0.35 mg talazoparib.

Talzenna 0.5 mg hard capsules
Each hard capsule contains talazoparib tosylate equivalent to 0.5 mg talazoparib.

Talzenna 1 mg hard capsules
Each hard capsule contains talazoparib tosylate equivalent to 1 mg talazoparib.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule (capsule).

TALZENNA 0.1 mg hard capsules
Hard capsule with white cap (printed with “Pfizer” in black) and a white body (printed with “TLZ 0.1” in black).

Talzenna 0.25 mg hard capsules
Opaque, approximately 14.30 mm x 5.32 mm hard capsule with an ivory cap (printed with “Pfizer” in black) and a white body (printed with “TLZ 0.25” in black).

TALZENNA 0.35 mg hard capsules
Hard capsule with ivory cap (printed with “Pfizer” in black) and an ivory body (printed with “TLZ 0.35” in black).

TALZENNA 0.5 mg hard capsules
Hard capsule with light pink cap (printed with “Pfizer” in black) and a white body (printed with “TLZ 0.5” in black).

Talzenna 1 mg hard capsules
Opaque, approximately 14.30 mm x 5.32 mm hard capsule with a light red cap (printed with “Pfizer” in black) and a white body (printed with “TLZ 1” in black).

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Breast cancer</u></p><p>Talzenna is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2‑mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments (see section 5.1). Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy.</p><p>&nbsp;</p><p><u>Prostate cancer</u></p><p>TALZENNA is indicated in combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) <em>[see section 4.2]</em>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with Talzenna should be initiated and supervised by a physician experienced in the use of anticancer medicinal products.</p><p>&nbsp;</p><p><u>Patient selection</u></p><p>&nbsp;</p><p><em>Breast cancer</em></p><p>Patients should be selected for the treatment of breast cancer with Talzenna based on the presence of deleterious or suspected deleterious germline BRCA mutations determined by an experienced laboratory using a validated test method.</p><p>&nbsp;</p><p>Genetic counselling for patients with BRCA mutations should be performed according to local regulations, as applicable.</p><p>&nbsp;</p><p><em>Prostate cancer</em></p><p>Select patients for the treatment of HRR gene-mutated mCRPC with TALZENNA based on the presence of HRR gene mutations (ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, or RAD51C) <em>[see section 4.1, section 5.1]</em>.</p><p>&nbsp;</p><p>An FDA-approved test for the detection of HRR gene mutations for use with TALZENNA is not currently available.</p><p>&nbsp;</p><p><u>Posology</u></p><p><u>&nbsp;</u></p><p><em>Breast Cancer</em></p><p>The recommended dose is 1&nbsp;mg talazoparib once daily. Patients should be treated until disease progression or unacceptable toxicity occurs.</p><p>&nbsp;</p><p><em>Prostate cancer</em></p><p>The recommended dosage of TALZENNA is 0.5 mg taken orally once daily in combination with enzalutamide until disease progression or unacceptable toxicity.</p><p>&nbsp;</p><p>Refer to the enzalutamide prescribing information for recommended enzalutamide dosing information.</p><p>&nbsp;</p><p>Patients receiving TALZENNA and enzalutamide should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.</p><p>&nbsp;</p><p><em>Missing dose</em></p><p>If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.</p><p>&nbsp;</p><p><em>Dose adjustments</em></p><p>To manage adverse drug reactions, interruption of treatment or dose reduction based on severity and clinical presentation should be considered (see Table 3). Recommended dose reductions are indicated in Table 1 and 2.</p><p>&nbsp;</p><p><strong>Table 1.&nbsp;&nbsp;&nbsp;&nbsp; Dose adjustments for toxicities for Breast Cancer</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Dose level</strong></p></td></tr><tr><td style="vertical-align:top"><p>Recommended starting dose</p></td><td style="vertical-align:top"><p>1&nbsp;mg (one 1&nbsp;mg capsule) once daily</p></td></tr><tr><td style="vertical-align:top"><p>First dose reduction</p></td><td style="vertical-align:top"><p>0.75&nbsp;mg (three 0.25&nbsp;mg capsules) once daily</p></td></tr><tr><td style="vertical-align:top"><p>Second dose reduction</p></td><td style="vertical-align:top"><p>0.5&nbsp;mg (two 0.25&nbsp;mg capsules) once daily</p></td></tr><tr><td style="vertical-align:top"><p>Third dose reduction</p></td><td style="vertical-align:top"><p>0.25&nbsp;mg (one 0.25&nbsp;mg capsule) once daily</p></td></tr></tbody></table><p>&nbsp;</p><p>Complete blood count should be obtained prior to starting Talzenna therapy and monitored monthly and as clinically indicated (see Table 3 and section 4.4).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:606px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Table 2.</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp; Dose adjustments for toxicities for Prostate cancer</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Dose Reductions</strong></p></td><td style="vertical-align:top"><p><strong>Dose Level</strong></p></td></tr><tr><td style="vertical-align:top"><p>Recommended starting dose</p></td><td style="vertical-align:top"><p>0.5 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>First dose reduction</p></td><td style="vertical-align:top"><p>0.35 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>Second dose reduction</p></td><td style="vertical-align:top"><p>0.25 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>Third dose reduction</p></td><td style="vertical-align:top"><p>0.1 mg once daily</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p>Refer to the enzalutamide prescribing information for dose modifications for adverse reactions associated with enzalutamide.</p><p>&nbsp;</p><p><strong>Table 3.&nbsp;&nbsp;&nbsp;&nbsp; Dose modification and management</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Withhold Talzenna until levels resolve to</strong></p></td><td style="vertical-align:top"><p><strong>Resume Talzenna</strong></p></td></tr><tr><td><p>Haemoglobin &lt;&nbsp;8&nbsp;g/dL</p></td><td><p>&ge;&nbsp;9&nbsp;g/dL</p></td><td rowspan="3"><p>Resume Talzenna at next lower dose</p></td></tr><tr><td><p>Platelet count &lt;&nbsp;50,000/&mu;L</p></td><td><p>&ge;&nbsp;75,000/&mu;L</p></td></tr><tr><td><p>Neutrophil count &lt;&nbsp;1,000/&mu;L</p></td><td><p>&ge;&nbsp;1,500/&micro;L</p></td></tr><tr><td><p>Non-haematologic adverse reaction Grade&nbsp;3 or Grade&nbsp;4</p></td><td><p>&pound;&nbsp;Grade 1</p></td><td><p>Consider resuming Talzenna at next lower dose or discontinue</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Concomitant treatment with inhibitors of P-glycoprotein (P‑gp)</em></p><p><em><u>&nbsp;</u></em></p><p><em><u>Breast cancer</u></em></p><p>Strong inhibitors of P‑gp may lead to increased talazoparib exposure. Concomitant use of strong P‑gp inhibitors during treatment with talazoparib should be avoided. Co-administration should only be considered after careful evaluation of the potential benefits and risks. If co-administration with a strong P‑gp inhibitor is unavoidable, the Talzenna dose should be reduced to the next lower dose. When the strong P-gp inhibitor is discontinued, the Talzenna dose should be increased (after 3‑5&nbsp;half‑lives of the P-gp inhibitor) to the dose used prior to the initiation of the strong P‑gp&nbsp;inhibitor (see section 4.5).</p><p>&nbsp;</p><p><em><u>Prostate cancer</u></em></p><p>The effect of coadministration of P-gp inhibitors on talazoparib exposure when TALZENNA is taken in combination with enzalutamide has not been studied. Monitor patients for increased adverse reactions and modify the dosage as recommended for adverse reactions when TALZENNA is coadministered with a P-gp inhibitor.</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dose adjustment is required for patients with mild hepatic impairment (total bilirubin &le;&nbsp;1&nbsp;&times;&nbsp;upper limit of normal [ULN] and aspartate aminotransferase (AST) &gt;&nbsp;ULN, or total bilirubin &gt;&nbsp;1.0 to 1.5&nbsp;&times;&nbsp;ULN and any AST), moderate hepatic impairment (total&nbsp;bilirubin&nbsp;&gt;&nbsp;1.5 to 3.0&nbsp;&times;&nbsp;ULN and any AST), or severe hepatic impairment (total bilirubin &gt;&nbsp;3.0&nbsp;&times;&nbsp;ULN and any AST) (see section 5.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment is required for patients with mild renal impairment (60&nbsp;mL/min &le;&nbsp;creatinine clearance [CrCL] &lt;&nbsp;90&nbsp;mL/min).</p><p>&nbsp;</p><p><em><u>Breast cancer</u></em></p><p>For patients with moderate renal impairment (30&nbsp;mL/min&nbsp;&le;&nbsp;CrCL&nbsp;&lt;&nbsp;60&nbsp;mL/min), the recommended starting dose of Talzenna is 0.75&nbsp;mg once daily.</p><p>For patients with severe renal impairment (15&nbsp;mL/min&nbsp;&le;&nbsp;CrCL&nbsp;&lt;&nbsp;30&nbsp;mL/min), the recommended starting dose of Talzenna is 0.5&nbsp;mg once daily. Talzenna has not been studied in patients with CrCL&nbsp;&lt;&nbsp;15&nbsp;mL/min or patients requiring haemodialysis (see section 5.2).</p><p><em><u>&nbsp;</u></em></p><p><em><u>Prostate cancer</u></em></p><p>The recommended dosage of TALZENNA for patients with moderate renal impairment (CLcr 30 - 59 mL/min) is 0.35 mg taken orally once daily in combination with enzalutamide.</p><p>The recommended dosage of TALZENNA for patients with severe renal impairment (CLcr 15 - 29 mL/min) is 0.25 mg taken orally once daily in combination with enzalutamide.</p><p>&nbsp;</p><p><em>Elderly </em></p><p>No dose adjustment is necessary in elderly (&ge;&nbsp;65&nbsp;years of age) patients (see section 5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Talzenna in children and adolescents &lt;&nbsp;18 years of age have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration </u></p><p>&nbsp;</p><p>Talzenna is for oral use. To avoid contact with the capsule content, the capsules should be swallowed whole, and must not be opened or dissolved. They can be taken with or without food (see section 5.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Breast-feeding (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Myelosuppression </u></p><p>&nbsp;</p><p>Myelosuppression consisting of anaemia, leucopenia/neutropenia, and/or thrombocytopenia, have been reported in patients treated with talazoparib (see section 4.8). Talazoparib should not be started until patients have recovered from haematological toxicity caused by previous therapy (&le;&nbsp;Grade 1).</p><p>&nbsp;</p><p>In TALAPRO-2, Grade &ge;3 anemia, neutropenia, and thrombocytopenia were reported, respectively, in 45%, 18%, and 8% of patients receiving TALZENNA and enzalutamide. Overall, 39% of patients (199/511) required a red blood cell transfusion, including 22% (111/511) who required multiple transfusions. Discontinuation due to anemia, neutropenia, and thrombocytopenia occurred, respectively, in 7%, 3%, and 0.4% of patients.</p><p>&nbsp;</p><p>Precautions should be taken to routinely monitor haematology parameters and signs and symptoms associated with anaemia, leucopenia/neutropenia, and/or thrombocytopenia in patients receiving talazoparib. If such events occur, dose modifications (reduction or interruption) are recommended (see section 4.2). Supportive care with or without blood and/or platelet transfusions and/or administration of colony stimulating factors may be used as appropriate.</p><p>&nbsp;</p><p><u>Myelodysplastic syndrome/Acute myeloid leukaemia</u></p><p>&nbsp;</p><p>Myelodysplastic syndrome/Acute Myeloid Leukaemia (MDS/AML) have been reported in patients who received poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors, including talazoparib. Overall, MDS/AML has been reported in &lt;&nbsp;1% of solid tumour patients treated with talazoparib in clinical studies. Potential contributing factors for the development of MDS/AML include previous platinum-containing chemotherapy, other DNA damaging agents or radiotherapy. Complete blood counts should be obtained at baseline and monitored monthly for signs of haematologic toxicity during treatment. If MDS/AML is confirmed, talazoparib should be discontinued.</p><p>&nbsp;</p><p>In TALAPRO-2, MDS/AML occurred in 2 out of 511 (0.4%) patients treated with TALZENNA and enzalutamide and in 0 out of 517 (0%) patients treated with placebo and enzalutamide <em>[see section 4.8]</em></p><p>&nbsp;</p><p><u>Contraception in women of childbearing potential</u></p><p>&nbsp;</p><p>Talazoparib was clastogenic in an <em>in&nbsp;vitro</em> chromosomal aberration assay in human peripheral blood lymphocytes and in an <em>in vivo </em>bone marrow micronucleus assay in rats but not mutagenic in Ames assay (see section 5.3), and may cause foetal harm when administered to a pregnant woman. Pregnant women should be advised of the potential risk to the foetus (see section 4.6). Women of childbearing potential should not become pregnant while receiving Talzenna and should not be pregnant at the beginning of treatment. A pregnancy test should be performed on all women of childbearing potential prior to treatment.</p><p>&nbsp;</p><p>A highly effective method of contraception is required for female patients during treatment with Talzenna, and for at least 7&nbsp;months after completing therapy. Since the use of hormonal contraception is not recommended in patients with breast cancer, two non-hormonal and complementary contraception methods should be used (see section 4.6).</p><p>&nbsp;</p><p>Male patients with female partners of reproductive potential or pregnant partners should be advised to use effective contraception (even after vasectomy), during treatment with Talzenna and for at least 4&nbsp;months after the final dose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Talazoparib is a substrate for drug transporters P-gp and Breast Cancer Resistance Protein (BCRP) and it is mainly eliminated by renal clearance as unchanged compound.</p><p>&nbsp;</p><p><u>Agents that may affect talazoparib plasma concentrations</u></p><p>&nbsp;</p><p>P-gp inhibitors</p><p><u>&nbsp;</u></p><p><em><u>Effect of enzalutamide</u></em></p><p>Coadministration of enzalutamide with TALZENNA increased talazoparib exposure approximately 2-fold.</p><p>The effect of coadministration of P-gp inhibitors on talazoparib exposure when TALZENNA is taken in combination with enzalutamide has not been studied. Monitor patients for increased adverse reactions and modify the dosage as recommended for adverse reactions when TALZENNA is coadministered with a P-gp inhibitor <em>[see section 4.2].</em></p><p><u>&nbsp;</u></p><p><u>Effect of other P-gp inhibitors</u></p><p>Data from a drug-drug interaction study in patients with advanced solid tumours indicated that co‑administration of multiple daily doses of a P-gp inhibitor, itraconazole 100&nbsp;mg twice daily with a single 0.5&nbsp;mg talazoparib dose increased talazoparib total exposure (AUC<sub>inf</sub>) and peak concentration (C<sub>max</sub>) by approximately 56% and 40%, respectively, relative to a single 0.5&nbsp;mg talazoparib dose administered alone. Population pharmacokinetic (PK) analysis has also shown that concomitant use of strong P-gp inhibitors increased talazoparib exposure by 45%, relative to talazoparib given alone.</p><p>&nbsp;</p><p>Concomitant use of strong P-gp inhibitors (including but not limited to amiodarone, carvedilol, clarithromycin, cobicistat, darunavir, dronedarone, erythromycin, indinavir, itraconazole, ketoconazole, lapatinib, lopinavir, propafenone, quinidine, ranolazine, ritonavir, saquinavir, telaprevir, tipranavir, and verapamil) should be avoided. If co-administration with a strong P-gp inhibitor is unavoidable, the Talzenna dose should be reduced (see section 4.2).</p><p>&nbsp;</p><p>P-gp inducers</p><p>Data from a drug-drug interaction study in patients with advanced solid tumours indicated that co‑administration of single 1&nbsp;mg talazoparib dose with multiple daily doses of a P-gp inducer, rifampin 600&nbsp;mg, with rifampin co-administered 30 minutes before talazoparib on the day of talazoparib dosing, increased talazoparib C<sub>max</sub> by approximately 37% whereas AUC<sub>inf </sub>was not affected relative to a single 1&nbsp;mg talazoparib dose administered alone. This is probably the net effect of both P-gp induction and inhibition by rifampin under the tested conditions in the drug-drug interaction study. No talazoparib dose adjustments are required when co‑administered with rifampin. However, the effect of other P-gp inducers on talazoparib exposure has not been studied. Other P-gp inducers (including but not limited to carbamazepine, phenytoin, and St.&nbsp;John&rsquo;s wort) may decrease talazoparib exposure.</p><p>&nbsp;</p><p>BCRP inhibitors</p><p>The effect of BCRP inhibitors on PK of talazoparib has not been studied <em>in vivo</em>. Co-administration of talazoparib with BCRP inhibitors may increase talazoparib exposure. Concomitant use of strong BCRP inhibitors (including but not limited to curcumin and cyclosporine) should be avoided. If co‑administration of strong BCRP inhibitors cannot be avoided, patient should be monitored for potential increased adverse reactions.</p><p>&nbsp;</p><p>Effect of acid-reducing agents</p><p>Population PK analysis indicates that co-administration of acid-reducing agents including proton pump inhibitors and histamine receptor 2 antagonists (H<sub>2</sub>RA), or other acid‑reducing agents had no significant impact on the absorption of talazoparib.</p><p>&nbsp;</p><p>Systemic hormonal contraception</p><p>Drug-drug interaction studies between talazoparib and oral contraceptives have not been conducted. &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/Contraception in males and females</u></p><p>&nbsp;</p><p>Women of childbearing potential should not become pregnant while receiving Talzenna and should not be pregnant at the beginning of treatment. A pregnancy test should be performed on all women of childbearing potential prior to treatment (see section 4.4).</p><p>&nbsp;</p><p>Women of childbearing potential must use highly effective forms of contraception (see section 4.4) prior to starting treatment with talazoparib, during treatment, and for 7 months after stopping treatment with talazoparib. Since the use of hormonal contraception is not recommended in patients with breast cancer, two non-hormonal and complementary contraception methods should be used. Male patients with female partners of reproductive potential or pregnant partners should be advised to use effective contraception (even after vasectomy) during treatment with Talzenna, and for at least 4&nbsp;months after the final dose (see section&nbsp;4.4).</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no data from the use of Talzenna in pregnant women. Studies in animals have shown embryo‑foetal toxicity (see section 5.3). Talzenna may cause foetal harm when administered to a pregnant woman. Talzenna is not recommended during pregnancy or for women of childbearing potential not using contraception (see section 4.4).</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is unknown whether talazoparib is excreted in human breast milk. A risk to breast-fed children cannot be excluded and therefore breast-feeding is not recommended during treatment with Talzenna and for at least 1 month after the final dose.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>There is no information on fertility in patients. Based on non-clinical findings in testes (partially reversible) and ovary (reversible), Talzenna may impair fertility in males of reproductive potential (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Talzenna may have a minor influence on the ability to drive and use machines. Fatigue/asthenia or dizziness may occur following administration of talazoparib.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile </u></p><p>&nbsp;</p><p>The overall safety profile of Talzenna is based on pooled data from 494&nbsp;patients who received talazoparib at 1&nbsp;mg daily in clinical studies for solid tumours, including 286&nbsp;patients from a randomised Phase&nbsp;3 study with germline BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer and 83&nbsp;patients from a nonrandomised Phase&nbsp;2 study in patients with germline BRCA-mutated locally advanced or metastatic breast cancer.</p><p>&nbsp;</p><p>The data described in Section 4.4 reflect exposure to TALZENNA 0.5 mg daily in combination with enzalutamide in 511 patients enrolled in the TALAPRO 2 trial that included 197 patients with HRR gene mutated mCRPC.</p><p>&nbsp;</p><p><em>Breast Cancer</em></p><p>The most common (&ge;&nbsp;25%) adverse reactions in patients receiving talazoparib in these clinical studies were fatigue (57.1%), anaemia (49.6%), nausea (44.3%), neutropenia (30.2%), thrombocytopenia (29.6%), and headache (26.5%). The most common (&ge;&nbsp;10%) Grade &ge;&nbsp;3 adverse reactions of talazoparib were anaemia (35.2%), neutropenia (17.4%), and thrombocytopenia (16.8%).</p><p>&nbsp;</p><p>Dose modifications (dose reductions or dose interruptions) due to any adverse reaction occurred in 62.3% of patients receiving Talzenna. The most common adverse reactions leading to dose modifications were anaemia (33.0%), neutropenia (15.8%), and thrombocytopenia (13.4%).</p><p>&nbsp;</p><p>Permanent discontinuation due to an adverse reaction occurred in 3.6% of patients receiving Talzenna. The median duration of exposure was 5.4 months (range 0.03-61.1).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Table 4 summarises adverse reactions based on pooled dataset listed by system organ class, and frequency category. Frequency categories are defined as: very common (&ge;&nbsp;1/10) and common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:612px"><thead><tr><td colspan="4" style="vertical-align:top"><p><strong>Table 4.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Adverse reactions based on pooled dataset from 5 studies (N=494)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p><p><strong>Frequency</strong></p><p><strong>Preferred term</strong></p></td><td><p><strong>All grades<sup>*</sup></strong></p><p><strong>n (%)</strong></p></td><td><p><strong>Grade 3</strong></p><p><strong>n (%)</strong></p></td><td><p><strong>Grade 4</strong></p><p><strong>n (%)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p><p><em>Very common</em></p><p>Thrombocytopenia<sup>a</sup></p><p>Anaemia<sup>b</sup></p><p>Neutropenia<sup>c</sup></p><p>Leucopenia<sup>d</sup></p><p><em>Common</em></p><p>Lymphopenia<sup>e</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>146 (29.6)</p><p>245 (49.6)</p><p>149 (30.2)</p><p>77 (15.6)</p><p>&nbsp;</p><p>30 (6.1)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>63 (12.8)</p><p>172 (34.8)</p><p>77 (15.6)</p><p>24 (4.9)</p><p>&nbsp;</p><p>13 (2.6)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>20 (4.0)</p><p>2 (0.4)</p><p>9 (1.8)</p><p>1 (0.2)</p><p>&nbsp;</p><p>0 (0.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p><p><em>Very common</em></p><p>Decreased appetite</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>100 (20.2)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>2 (0.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>0 (0.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p><p><em>Very common</em></p><p>Dizziness</p><p>Headache</p><p><em>Common</em></p><p>Dysgeusia</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>69 (14.0)</p><p>131 (26.5)</p><p>&nbsp;</p><p>42 (8.5)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>1 (0.2)</p><p>5 (1.0)</p><p>&nbsp;</p><p>0 (0.0)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>N/A</p><p>N/A</p><p>&nbsp;</p><p>0 (0.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p><p><em>Very common</em></p><p>Vomiting</p><p>Diarrhoea</p><p>Nausea</p><p>Abdominal pain<sup>f</sup></p><p><em>Common</em></p><p>Stomatitis</p><p>Dyspepsia</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>110 (22.3)</p><p>112 (22.7)</p><p>219 (44.3)</p><p>105 (21.3)</p><p>&nbsp;</p><p>32 (6.5)</p><p>41 (8.3)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>7 (1.4)</p><p>3 (0.6)</p><p>4 (0.8)</p><p>8 (1.6)</p><p>&nbsp;</p><p>0 (0.0)</p><p>0 (0.0)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>0 (0.0)</p><p>0 (0.0)</p><p>N/A</p><p>N/A</p><p>&nbsp;</p><p>0 (0.0)</p><p>N/A</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p><p><em>Very common</em></p><p>Alopecia<sup>g</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>110 (22.3)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>N/A</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>N/A</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p><p><em>Very common</em></p><p>Fatigue<sup>h</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>282 (57.1)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>17 (3.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>1 (0.2)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Abbreviations: n=number of patients; N/A=not applicable.</p><p><sup>*</sup>&nbsp;&nbsp;&nbsp; There were no Grade 5 adverse drug reactions.</p><p><sup>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Includes preferred terms of thrombocytopenia and platelet count decreased.</p><p><sup>b.&nbsp;&nbsp;&nbsp;&nbsp; </sup>Includes preferred terms of anaemia, haematocrit decreased and haemoglobin decreased.</p><p><sup>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Includes preferred terms of neutropenia and neutrophil count decreased.</p><p><sup>d.&nbsp;&nbsp;&nbsp;&nbsp; </sup>Includes preferred terms of leucopenia and white blood cell count decreased.</p><p><sup>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Includes preferred terms of lymphocyte count decreased and lymphopenia.</p><p><sup>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Includes preferred terms of abdominal pain, abdominal pain upper, abdominal discomfort and abdominal pain lower.</p><p><sup>g.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>For talazoparib Grade 1 is 21% and Grade 2 is 2%.</p><p><sup>h.&nbsp;&nbsp;&nbsp;&nbsp; </sup>Includes preferred terms of fatigue and asthenia.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Prostate cancer</em></p><p>The safety of TALZENNA in combination with enzalutamide was evaluated in patients with HRR gene‑mutated mCRPC enrolled in TALAPRO-2<em> [see section 5.1]</em>. Patients were randomized to receive either TALZENNA 0.5 mg in combination with enzalutamide 160 mg once daily (n=197), or placebo in enzalutamide 160 mg once daily (n=199) until disease progression or unacceptable toxicity. Among patients receiving TALZENNA, 86% were exposed for 6 months or longer, 60% were exposed for greater than one year, and 18% were exposed for greater than two years.</p><p>&nbsp;</p><p>Serious adverse reactions of TALZENNA in combination with enzalutamide occurred in 30% of patients. Serious adverse reactions reported in &gt;2% of patients included anemia (9%) and fracture (3%). Fatal adverse reactions occurred in 1.5% of patients, including pneumonia, COVID infection, and sepsis (1&nbsp;patient each).</p><p>&nbsp;</p><p>Permanent discontinuation of TALZENNA due to adverse reactions occurred in 10% of patients treated in the TALZENNA with enzalutamide arm. The most common adverse reactions which resulted in permanent discontinuation of TALZENNA were anemia (4%), fatigue, bone fracture, ischemic heart disease, and spinal cord compression (1% each).</p><p>&nbsp;</p><p>Dosage interruption of TALZENNA due to adverse reactions occurred in 58% of patients treated in the TALZENNA with enzalutamide arm. The most common adverse reactions which resulted in dose interruption of TALZENNA were anemia (42%), neutropenia (15%), and platelet count decreased (9%) and fatigue (5%).</p><p>&nbsp;</p><p>Dose reduction of TALZENNA due to adverse reactions occurred in 52% of patients treated in the TALZENNA with enzalutamide arm. The most common adverse reactions which resulted in dose reduction of TALZENNA were anemia (43%), neutrophil count decreased (15%), platelet count decreased (6%), and fatigue (4%).</p><p>&nbsp;</p><p>The most common adverse reactions (&ge;10%), including laboratory abnormalities, in patients who received TALZENNA with enzalutamide were hemoglobin decreased, neutrophils decreased, lymphocytes decreased, fatigue, platelets decreased, calcium decreased, nausea, decreased appetite, sodium decreased, phosphate decreased, fractures, magnesium decreased, dizziness, bilirubin increased, potassium decreased, and dysgeusia.</p><p>&nbsp;</p><p>Table 5 and Table 6 summarize the most common adverse reactions and laboratory abnormalities, respectively, in the TALAPRO-2 study.</p><p>&nbsp;</p><p><strong>Table 5.&nbsp;&nbsp;&nbsp;&nbsp; Adverse Reactions<sup>a</sup> (</strong><strong>&ge;</strong><strong>10%) in Patients Receiving TALZENNA [with a Difference Between Arms of </strong><strong>&ge;</strong><strong>2%] in TALAPRO-2</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:606px"><tbody><tr><td rowspan="2">&nbsp;</td><td colspan="3" style="vertical-align:top"><p><strong>TALZENNA&nbsp;with Enzalutamide</strong></p><p><strong>N=197</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Placebo with Enzalutamide</strong></p><p><strong>N=199</strong></p></td></tr><tr><td><p><strong>Grades 1-4</strong></p><p><strong>%</strong></p></td><td><p><strong>Grade 3</strong></p><p><strong>%</strong></p></td><td><p><strong>Grade 4</strong></p><p><strong>%</strong></p></td><td><p><strong>Grades 1-4</strong></p><p><strong>%</strong></p></td><td><p><strong>Grade 3</strong></p><p><strong>%</strong></p></td><td><p><strong>Grade 4</strong></p><p><strong>%</strong></p></td></tr><tr><td><p>Fatigue<sup>b</sup></p></td><td><p>49</p></td><td><p>4</p></td><td><p>0</p></td><td><p>40</p></td><td><p>1</p></td><td><p>0</p></td></tr><tr><td><p>Nausea</p></td><td><p>21</p></td><td><p>2</p></td><td><p>0</p></td><td><p>17</p></td><td><p>1</p></td><td><p>0.5</p></td></tr><tr><td><p>Decreased appetite</p></td><td><p>20</p></td><td><p>1</p></td><td><p>0</p></td><td><p>14</p></td><td><p>1</p></td><td><p>1</p></td></tr><tr><td><p>Fractures<sup>c</sup></p></td><td><p>14</p></td><td><p>3</p></td><td><p>0</p></td><td><p>10</p></td><td><p>1.5</p></td><td><p>0</p></td></tr><tr><td><p>Dizziness<sup>d</sup></p></td><td><p>13</p></td><td><p>1.5</p></td><td><p>0</p></td><td><p>9</p></td><td><p>1.5</p></td><td><p>0</p></td></tr><tr><td><p>Dysgeusia<sup>e</sup></p></td><td><p>10</p></td><td><p>0</p></td><td><p>0</p></td><td><p>4.5</p></td><td><p>0</p></td><td><p>0</p></td></tr></tbody></table><p>Abbreviation: N=number of patients.</p><p><sup>a.</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Graded according to NCI CTCAE 4.03.</p><p><sup>b.</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes fatigue and asthenia.</p><p><sup>c.</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fractures include multiple similar terms.</p><p><sup>d.</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes dizziness, dizziness postural, vertigo.</p><p><sup>e.</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes ageusia, anosmia, dysgeusia.</p><p>&nbsp;</p><p>Clinically relevant adverse reactions in &lt;10% of patients who received TALZENNA with enzalutamide included abdominal pain (9%), vomiting (9%), alopecia (7%), dyspepsia (4%), venous thromboembolism (3%) and stomatitis (2%).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:612px"><tbody><tr><td colspan="7" style="vertical-align:top"><p><strong>Table&nbsp;6.</strong>&nbsp;&nbsp;&nbsp;&nbsp; <strong>Select Laboratory Abnormalities (&ge;10%) That Worsened from Baseline in Patients Who Received TALZENNA in TALAPRO-2</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>Laboratory Abnormality</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>TALZENNA with Enzalutamide</strong></p><p><strong>N=197<sup>a</sup></strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Placebo with Enzalutamide</strong></p><p><strong>N=199<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Grades 1‑4</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Grade 4</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Grades 1‑4</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Grade 4</strong></p><p><strong>%</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hemoglobin decreased</p></td><td style="vertical-align:top"><p>79</p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Neutrophils decreased</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Lymphocytes decreased</p></td><td style="vertical-align:top"><p>58</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Platelets decreased</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Calcium decreased</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Sodium decreased</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Phosphate decreased</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Magnesium decreased</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td style="vertical-align:top"><p>Bilirubin increased</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Potassium decreased</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0.5</p></td></tr></tbody></table><p>Abbreviation: N=number of patients.</p><p>0.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The denominator used to calculate the rate varied from 198 to 199 in the placebo with enzalutamide arm based on the number of patients with a baseline value and at least one post-treatment value.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Myelosuppression</em></p><p>Myelosuppression-related adverse reactions of anaemia, neutropenia, and thrombocytopenia were very commonly reported in patients treated with talazoparib 1&nbsp;mg/day. Grade&nbsp;3 and Grade 4 myelosuppression‑related events were reported for anaemia 34.8% and 0.4%, neutropenia 15.6% and 1.8%, and thrombocytopenia 12.8% and 4.0%. No&nbsp;deaths were reported due to myelosuppression‑related adverse reactions. Myelosuppression‑related adverse events associated with dose modifications were reported for up to approximately 30% of patients in the talazoparib 1&nbsp;mg/day population and those associated with permanent study drug discontinuation were reported for less than 1% of patients.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via National Pharmacovigilance Centre (NPC).</p><p><u>&nbsp;</u></p><p><strong>To report any side effects:</strong></p><p><u>&nbsp;</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance (NPC)</p><ul><li>SFDA Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa<u> </u></li><li>Website: https://ade.sfda.gov.sa/</li></ul></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p><em>&nbsp;</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific treatment in the event of TALZENNA overdose, and symptoms of overdose have not been established. In the event of overdose, discontinue treatment with TALZENNA, consider gastric decontamination, follow general supportive measures, and treat symptomatically.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: other antineoplastic agents, ATC code: L01XK04</p><p>&nbsp;</p><p><u>Mechanism of action </u></p><p>&nbsp;</p><p>Talazoparib is an inhibitor of PARP enzymes, PARP1, and PARP2. PARP enzymes are involved in cellular DNA damage response signalling pathways such as DNA repair, gene transcription, and cell death. PARP inhibitors (PARPi) exert cytotoxic effects on cancer cells by 2&nbsp;mechanisms, inhibition of PARP catalytic activity and by PARP trapping, whereby PARP protein bound to a PARPi does not readily dissociate from a DNA lesion, thus preventing DNA repair, replication, and transcription, thereby resulting in apoptosis and/or cell death. Treatment of cancer cell lines that are harbouring defects in DNA repair genes with talazoparib single agent leads to increased levels of &gamma;H2AX, a marker of double stranded DNA breaks, and results in decreased cell proliferation and increased apoptosis. Talazoparib anti-tumour activity was also observed in a patient-derived xenograft (PDX) BRCA mutant breast cancer model where the patient was previously treated with a platinum-based regimen. In this PDX model talazoparib decreased tumour growth and increased &gamma;H2AX level and apoptosis in the tumours.</p><p>&nbsp;</p><p><u>Cardiac electrophysiology</u></p><p>&nbsp;</p><p>The effect of talazoparib on cardiac repolarisation was evaluated using time-matched electrocardiograms (ECGs) in assessing the relationship between the change of the QT interval corrected for heart rate (QTc) from baseline and the corresponding plasma talazoparib concentrations in 37 patients with advanced solid tumours. Talazoparib did not have a clinically relevant effect on QTc prolongation at the maximum clinically recommended dose of 1&nbsp;mg once daily.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety </u></p><p>&nbsp;</p><p><strong>Breast Cancer</strong></p><p>&nbsp;</p><p><em>Randomised phase 3 study EMBRACA</em></p><p>EMBRACA was an open-label, randomised, parallel, 2-arm multicentre study of Talzenna versus chemotherapy (capecitabine, eribulin, gemcitabine, vinorelbine) in patients with germline BRCA‑mutated HER2‑negative locally advanced or metastatic breast cancer who received no more than 3 prior cytotoxic chemotherapy regimens for their metastatic or locally advanced disease. Patients were required to have received treatment with an anthracycline and/or a taxane (unless contraindicated) in the neoadjuvant, adjuvant and/or metastatic setting. Patients with prior platinum therapy for advanced disease were required to have no evidence of disease progression during platinum therapy. No prior treatment with a PARP inhibitor was permitted.</p><p>&nbsp;</p><p>Of the 431 patients randomised in the EMBRACA study, 408 (95%) were centrally confirmed to have a deleterious or suspected deleterious gBRCAm using a clinical trial assay; out of which 354 (82%) were confirmed using the BRACAnalysis CDx<sup>&reg;</sup>. BRCA mutation status (breast cancer susceptibility gene 1 [BRCA1] positive or breast cancer susceptibility gene 2 [BRCA2] positive) was similar across both treatment arms.</p><p>&nbsp;</p><p>A total of 431 patients were randomised 2:1 to receive Talzenna 1&nbsp;mg capsules once daily or chemotherapy at standard doses until progression or unacceptable toxicity. Of the 431 patients randomised onto EMBRACA, 287 were randomised to the Talzenna arm and 144 to the chemotherapy arm. Randomisation was stratified by prior use of chemotherapy for metastatic disease (0 versus 1, 2, or 3), by triple-negative disease status (triple-negative breast cancer [TNBC] versus non-TNBC), and history of central nervous system metastasis (yes versus no).</p><p>&nbsp;</p><p>Patient demographic, baseline, and disease characteristics were generally similar between the study treatment arms (see Table 7).</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="3" style="vertical-align:top"><p>Table&nbsp;7.&nbsp;&nbsp;&nbsp;&nbsp; Demographic, baseline, and disease characteristics &ndash; EMBRACA study</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Talazoparib</p><p><strong>(N=287)</strong></p></td><td style="vertical-align:top"><p>Chemotherapy</p><p><strong>(N=144)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Median age (y [range])</p></td><td style="vertical-align:top"><p>45.0 (27.0, 84.0)</p></td><td style="vertical-align:top"><p>50.0 (24.0, 88.0)</p></td></tr><tr><td style="vertical-align:top"><p>Age category (y), n (%)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&lt;&nbsp;50</p></td><td style="vertical-align:top"><p>182 (63.4%)</p></td><td style="vertical-align:top"><p>67 (46.5%)</p></td></tr><tr><td style="vertical-align:top"><p>50 to &lt;&nbsp;65</p></td><td style="vertical-align:top"><p>78 (27.2%)</p></td><td style="vertical-align:top"><p>67 (46.5%)</p></td></tr><tr><td style="vertical-align:top"><p>&ge;&nbsp;65</p></td><td style="vertical-align:top"><p>27 (9.4%)</p></td><td style="vertical-align:top"><p>10 (6.9%)</p></td></tr><tr><td style="vertical-align:top"><p>Gender, n (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Female</p></td><td style="vertical-align:top"><p>283 (98.6%)</p></td><td style="vertical-align:top"><p>141 (97.9%)</p></td></tr><tr><td style="vertical-align:top"><p>Male</p></td><td style="vertical-align:top"><p>4 (1.4%)</p></td><td style="vertical-align:top"><p>3 (2.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Race, n (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Asian</p></td><td style="vertical-align:top"><p>31 (10.8%)</p></td><td style="vertical-align:top"><p>16 (11.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Black or African American</p></td><td style="vertical-align:top"><p>12 (4.2%)</p></td><td style="vertical-align:top"><p>1 (0.7%)</p></td></tr><tr><td style="vertical-align:top"><p>White</p></td><td style="vertical-align:top"><p>192 (66.9%)</p></td><td style="vertical-align:top"><p>108 (75.0%)</p></td></tr><tr><td style="vertical-align:top"><p>Other</p></td><td style="vertical-align:top"><p>5 (1.7%)</p></td><td style="vertical-align:top"><p>1 (0.7%)</p></td></tr><tr><td style="vertical-align:top"><p>Not reported</p></td><td style="vertical-align:top"><p>47 (16.4%)</p></td><td style="vertical-align:top"><p>18 (12.5%)</p></td></tr><tr><td style="vertical-align:top"><p>ECOG performance status, n (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>153 (53.3%)</p></td><td style="vertical-align:top"><p>84 (58.3%)</p></td></tr><tr><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>127 (44.3%)</p></td><td style="vertical-align:top"><p>57 (39.6%)</p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>6 (2.1%)</p></td><td style="vertical-align:top"><p>2 (1.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Missing</p></td><td style="vertical-align:top"><p>1 (0.3%)</p></td><td style="vertical-align:top"><p>1 (0.7%)</p></td></tr><tr><td style="vertical-align:top"><p>Hormone receptor status, n (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>HER2-positive</p></td><td style="vertical-align:top"><p>0 (0.0%)</p></td><td style="vertical-align:top"><p>0 (0.0%)</p></td></tr><tr><td style="vertical-align:top"><p>Triple‑negative</p></td><td style="vertical-align:top"><p>130 (45.3%)</p></td><td style="vertical-align:top"><p>60 (41.7%)</p></td></tr><tr><td style="vertical-align:top"><p>Hormone receptor‑positive (ER&nbsp;positive or PgR&nbsp;positive)</p></td><td style="vertical-align:top"><p>157 (54.7%)</p></td><td style="vertical-align:top"><p>84 (58.3%)</p></td></tr><tr><td style="vertical-align:top"><p>BRCA status by central or local laboratory assessment, n&nbsp;(%)</p></td><td style="vertical-align:top"><p>287 (100.0%)</p></td><td style="vertical-align:top"><p>144 (100.0%)</p></td></tr><tr><td style="vertical-align:top"><p>BRCA1‑mutation positive</p></td><td style="vertical-align:top"><p>133 (46.3%)</p></td><td style="vertical-align:top"><p>63 (43.8%)</p></td></tr><tr><td style="vertical-align:top"><p>BRCA2‑mutation positive</p></td><td style="vertical-align:top"><p>154 (53.7%)</p></td><td style="vertical-align:top"><p>81 (56.3%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Time from initial diagnosis of breast cancer to diagnosis of advanced breast cancer (years)</p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>286</p></td><td style="vertical-align:top"><p>144</p></td></tr><tr><td style="vertical-align:top"><p>Median</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>2.7</p></td></tr><tr><td style="vertical-align:top"><p>Minimum, maximum</p></td><td style="vertical-align:top"><p>0, 22</p></td><td style="vertical-align:top"><p>0, 24</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Categories for time from initial diagnosis of breast cancer to diagnosis of advanced breast cancer</p></td></tr><tr><td style="vertical-align:top"><p>&lt;&nbsp;12 months</p></td><td style="vertical-align:top"><p>108 (37.6%)</p></td><td style="vertical-align:top"><p>42 (29.2%)</p></td></tr><tr><td style="vertical-align:top"><p>&ge;&nbsp;12 months</p></td><td style="vertical-align:top"><p>178 (62.0%)</p></td><td style="vertical-align:top"><p>102 (70.8%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Number of prior cytotoxic regimens for locally advanced or metastatic disease</p></td></tr><tr><td style="vertical-align:top"><p>Mean (Std Dev)</p></td><td style="vertical-align:top"><p>0.9 (1.01)</p></td><td style="vertical-align:top"><p>0.9 (0.89)</p></td></tr><tr><td style="vertical-align:top"><p>Median</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Minimum, maximum</p></td><td style="vertical-align:top"><p>0, 4</p></td><td style="vertical-align:top"><p>0, 3</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Number of patients who received prior cytotoxic regimens for locally advanced or metastatic disease, n (%)</p></td></tr><tr><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>111 (38.7%)</p></td><td style="vertical-align:top"><p>54 (37.5%)</p></td></tr><tr><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>107 (37.3%)</p></td><td style="vertical-align:top"><p>54 (37.5%)</p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>57 (19.9%)</p></td><td style="vertical-align:top"><p>28 (19.4%)</p></td></tr><tr><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>11 (3.8%)</p></td><td style="vertical-align:top"><p>8 (5.6%)</p></td></tr><tr><td style="vertical-align:top"><p>&ge;&nbsp;4</p></td><td style="vertical-align:top"><p>1 (0.3%)</p></td><td style="vertical-align:top"><p>0 (0.0%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Number of patients who received following prior therapies, n (%)</p></td></tr><tr><td style="vertical-align:top"><p>Taxane</p></td><td style="vertical-align:top"><p>262 (91.3%)</p></td><td style="vertical-align:top"><p>130 (90.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Anthracycline</p></td><td style="vertical-align:top"><p>243 (84.7%)</p></td><td style="vertical-align:top"><p>115 (79.9%)</p></td></tr><tr><td style="vertical-align:top"><p>Platinum</p></td><td style="vertical-align:top"><p>46 (16.0%)</p></td><td style="vertical-align:top"><p>30 (20.8%)</p></td></tr></tbody></table><p>Abbreviations: BRCA=breast cancer susceptibility gene; ER=estrogen receptor; HER2=human epidermal growth factor receptor&nbsp;2; N=number of patients; n=number of patients in category; PgR=progesterone receptor.</p><p>&nbsp;</p><p>The primary efficacy endpoint was progression-free survival (PFS) evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as assessed by blinded independent central review (BICR). The secondary objectives were objective response rate (ORR), overall survival (OS), safety, and PK.</p><p>&nbsp;</p><p>The study demonstrated a statistically significant improvement in PFS, the primary efficacy outcome, for Talzenna compared with chemotherapy. There was no statistically significant effect on OS at the time of final OS analysis. Efficacy data for EMBRACA are summarised in Table 8. The Kaplan-Meier curves for PFS and OS are displayed in Figure 1 and Figure 3, respectively.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="3" style="vertical-align:top"><p>Table&nbsp;8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Summary of efficacy results &ndash; EMBRACA study<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Talazoparib</p></td><td style="vertical-align:top"><p>Chemotherapy</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>PFS by BICR</p></td><td style="vertical-align:top"><p>N=287</p></td><td style="vertical-align:top"><p>N=144</p></td></tr><tr><td style="vertical-align:top"><p>Events, number (%)</p></td><td><p>186 (65%)</p></td><td><p>83 (58%)</p></td></tr><tr><td style="vertical-align:top"><p>Median (95% CI), months</p></td><td style="vertical-align:top"><p>8.6 (7.2, 9.3)</p></td><td style="vertical-align:top"><p>5.6 (4.2, 6.7)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>a</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.54 (0.41, 0.71)</p></td></tr><tr><td style="vertical-align:top"><p>2-sided p-value<sup>b</sup></p></td><td colspan="2" style="vertical-align:top"><p>p&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>OS (final analysis)<sup>c</sup></p></td><td style="vertical-align:top"><p>N=287</p></td><td style="vertical-align:top"><p>N=144</p></td></tr><tr><td style="vertical-align:top"><p>Events, number (%)</p></td><td><p>216 (75.3%)</p></td><td><p>108 (75%)</p></td></tr><tr><td style="vertical-align:top"><p>Median (95% CI), months</p></td><td style="vertical-align:top"><p>19.3 (16.6, 22.5)</p></td><td style="vertical-align:top"><p>19.5 (17.4, 22.4)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>a</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.85 (0.67, 1.07)<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>2-sided p-value<sup>b</sup></p></td><td colspan="2" style="vertical-align:top"><p>p=0.1693</p></td></tr><tr><td style="vertical-align:top"><p>Objective response by investigator<sup>d,e</sup></p></td><td style="vertical-align:top"><p>N=219</p></td><td style="vertical-align:top"><p>N=114</p></td></tr><tr><td style="vertical-align:top"><p>ORR, % (95% CI)</p></td><td style="vertical-align:top"><p>62.6 (55.8, 69.0)</p></td><td style="vertical-align:top"><p>27.2 (19.3, 36.3)</p></td></tr><tr><td style="vertical-align:top"><p>Odds ratio (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>4.99 (2.93, 8.83)</p></td></tr><tr><td style="vertical-align:top"><p>2-sided p-value<sup>f</sup></p></td><td colspan="2" style="vertical-align:top"><p>p&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Duration of response by investigator<sup>d</sup></p></td><td style="vertical-align:top"><p>N=137</p></td><td style="vertical-align:top"><p>N=31</p></td></tr><tr><td style="vertical-align:top"><p>Median (IQR), months</p></td><td style="vertical-align:top"><p>5.4 (2.8, 11.2)</p></td><td style="vertical-align:top"><p>3.1 (2.4, 6.7)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Abbreviations: BICR=blinded independent central review; CI=confidence interval; CMH=Cochran‑Mantel‑Haenszel; CR=complete response; IQR=interquartile range; ITT=intent‑to‑treat; ORR=objective response rate; OS=overall survival; PARP=poly (adenosine diphosphate‑ribose) polymerase; PFS=progression-free survival; PR=partial response; RECIST 1.1=Response Evaluation Criteria in Solid Tumors version 1.1.</p><p><sup>*</sup>&nbsp;&nbsp;&nbsp; PFS, ORR and Duration of response are based on the data cutoff date of 15 September 2017 and a median follow-up for PFS of 13.0 months (95% CI: 11.1, 18.4) in the talazoparib arm and 7.2 months (95% CI: 4.6, 11.1) in the chemotherapy arm. OS is based on the data cutoff date 30 September 2019 and a median follow-up of 44.9 months (95% CI: 37.9, 47.0) in the talazoparib arm and 36.8&nbsp;months (95% CI: 34.3, 43.0) in the chemotherapy arm.</p><p><sup>a.</sup>&nbsp;&nbsp;&nbsp; Hazard ratio was based on stratified Cox regression model with treatment as the only covariate (stratification factors: number of prior cytotoxic chemotherapy regimens, triple-negative status, history of central nervous system metastasis) and was relative to overall chemotherapy with &lt;&nbsp;1 favouring talazoparib.</p><p><sup>b.</sup>&nbsp;&nbsp; Stratified log-rank test.</p><p><sup>c.</sup>&nbsp;&nbsp;&nbsp; At the time of the final OS analysis, 46.3% versus 41.7% of patients randomised in the talazoparib and chemotherapy arms, respectively, received subsequently a platinum therapy, and 4.5% versus 32.6% received subsequently a PARP inhibitor treatment.</p><p><sup>d.</sup>&nbsp;&nbsp; Conducted in ITT with measurable disease population who had an objective response. The complete response rate was 5.5% for talazoparib compared to 0% for the chemotherapy arm.</p><p><sup>e.</sup>&nbsp;&nbsp;&nbsp; Per RECIST 1.1, confirmation of CR/PR was not required.</p><p><sup>f.</sup>&nbsp;&nbsp;&nbsp; Stratified CMH test.</p></td></tr></tbody></table><p>&nbsp;</p><p>Figure 1.&nbsp;&nbsp;&nbsp; Kaplan-Meier curves of PFS &ndash; EMBRACA study</p><p>&nbsp;</p><p><!--[if gte mso 9]><xml>
 <o:OLEObject Type="Embed" ProgID="SPLUSGraphSheetFileType"
  ShapeID="_x0000_i1025" DrawAspect="Content" ObjectID="_1784877748">
 </o:OLEObject>
</xml><![endif]--></p><p>Abbreviations: CI=confidence interval; PFS=progression-free survival.</p><p>&nbsp;</p><p>A series of prespecified subgroup PFS analyses was performed based on prognostic factors and baseline characteristics to investigate the internal consistency of treatment effect. Consistent with the overall results, a reduction in the risk of disease progression or death in favour of the talazoparib arm was observed in all individual patient subgroups (Figure 2).</p><p>&nbsp;</p><p>Figure 2.&nbsp;&nbsp;&nbsp; Forest plot of PFS analyses for key subgroups &ndash; EMBRACA study</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:593px"><tbody><tr><td style="vertical-align:top"><p><br />Abbreviations: aBC=advanced breast cancer; CI=confidence interval; CNS=central nervous system; HR+=hormone receptor-positive; ITT=intent-to-treat; PCT=physician&rsquo;s choice treatment (chemotherapy); PFS=progression-free survival; TNBC=triple-negative breast cancer.</p></td></tr></tbody></table><p>&nbsp;</p><p>Figure 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kaplan-Meier curves of overall survival &ndash; EMBRACA study</p><p>&nbsp;</p><p>&nbsp;</p><p>Abbreviations: CI=confidence interval; OS=overall survival.</p><p>Primary analysis&rsquo; p-value was based on a stratified log-rank test.</p><p><u>&nbsp;</u></p><p><strong>Prostate cancer </strong></p><p>&nbsp;</p><p>The efficacy of TALZENNA in combination with enzalutamide was evaluated in TALAPRO-2 (NCT03395197), a randomized, double-blind, placebo-controlled, multi-cohort trial in which 399 patients with HRR gene-mutated (HRRm) mCRPC were randomized 1:1 to receive enzalutamide 160 mg daily plus either TALZENNA 0.5 mg or placebo daily until unacceptable toxicity or progression. All patients received a GnRH analog or had prior bilateral orchiectomy and needed to have progressed on prior androgen deprivation therapy. Prior treatment with a CYP17 inhibitor or docetaxel for metastatic castration-sensitive prostate cancer (mCSPC) was permitted. Mutation status of HRR genes was determined prospectively using solid tumor tissue or circulating tumor DNA (ctDNA)-based next generation sequencing assays. Patients were required to have a mutation in at least one of 12 genes involved in the HRR pathway (<em>ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, </em>or<em> RAD51C</em>).</p><p>&nbsp;</p><p>Randomization was stratified by previous treatment with a CYP17 inhibitor or docetaxel (yes/no).</p><p>&nbsp;</p><p>The median age was 70 years (range: 41 to 90); 100% were male; 68% were White, 21% Asian, 2.8% Black, 0.8% Other, 7% unknown/not reported; 12% were Hispanic/Latino; and baseline ECOG performance status was 0 (62%) or 1 (38%). Thirty-nine percent of patients had bone-only disease; 15% had visceral disease. In the mCSPC setting, 29% percent of patients had received docetaxel and 9% had received a prior CYP17 inhibitor. The most commonly mutated HRR genes (&gt;5%), including co-occurring mutations, were: <em>BRCA2 </em>(34%), <em>ATM</em> (22%), <em>CDK12</em> (19%), <em>CHEK2</em> (18%), and <em>BRCA1</em> (6%).</p><p>&nbsp;</p><p>The major efficacy outcome measure was radiographic progression-free survival (rPFS) evaluated according to RECIST, version 1.1 and Prostate Cancer Working Group (PCWG3) (bone) criteria, assessed by BICR. An additional efficacy outcome measure was OS.</p><p>&nbsp;</p><p>A statistically significant improvement in rPFS was demonstrated at the pre-specified interim analysis in patients randomized to TALZENNA in combination with enzalutamide compared with placebo in combination with enzalutamide. Consistent rPFS results were observed in patients who received or did not receive a prior CYP17 inhibitor or docetaxel. The OS data were not mature at the time of the rPFS analysis (24% of patients had died). Efficacy results are presented in Table 9 and Figure 4.</p><p>&nbsp;</p><p>Table 9.&nbsp;&nbsp;&nbsp;&nbsp; Efficacy Results for TALAPRO-2 (HRR Gene-mutated mCRPC)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>TALZENNA with Enzalutamide</strong></p><p><strong>(N=200)</strong></p></td><td style="vertical-align:bottom"><p><strong>Placebo with Enzalutamide</strong></p><p><strong>(N=199)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Radiographic Progression-free Survival (rPFS) by BICR</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of rPFS events, n (%)</p></td><td style="vertical-align:top"><p>66 (33)</p></td><td style="vertical-align:top"><p>104 (52)</p></td></tr><tr><td style="vertical-align:top"><p>Median months (95% CI)</p></td><td style="vertical-align:top"><p>NE (21.9, NE)</p></td><td style="vertical-align:top"><p>13.8 (11.0, 16.7)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI)*</p></td><td colspan="2" style="vertical-align:top"><p>0.45 (0.33, 0.61)</p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>&dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr></tbody></table><p>Abbreviations: BICR=blinded independent central review; CI=confidence interval; CSPC=castration-sensitive prostate cancer; HRRm=homologous recombination repair gene-mutated; mCRPC=metastatic castration-resistant prostate cancer; N=number of patients; NE=not evaluable.</p><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hazard ratio and CI were based on Cox PH model stratified by previous treatment for CSPC.</p><p><sup>&dagger;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>p-value was based on log-rank test stratified by previous treatment for CSPC and compared with the boundary 0.0076.</p><p>&nbsp;</p><p><strong>Figure 4.</strong>&nbsp;&nbsp;&nbsp; <strong>Kaplan-Meier Curve for rPFS in TALAPRO-2 (HRR Gene-mutated mCRPC)</strong></p><p>&nbsp;</p><p>Abbreviations: HRRm=homologous recombination repair gene-mutated; mCRPC=metastatic castration-resistant prostate cancer; rPFS=radiographic progression-free survival.</p><p>&nbsp;</p><p>Exploratory subgroup analyses of rPFS for patients with BRCA-mutated (BRCAm) and non-BRCAm HRRm are presented in Table 10.</p><p>&nbsp;</p><p>Table 10.&nbsp;&nbsp; Exploratory rPFS Subgroup Analyses by BRCAm Status for TALAPRO-2 (HRR Gene‑mutated mCRPC)</p><table border="1" cellspacing="0" cellpadding="0" style="width:606px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2"><p><strong>BRCAm</strong></p></td><td colspan="2"><p><strong>Non-BRCAm HRRm*</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>TALZENNA with Enzalutamide</strong></p><p><strong>N=71</strong></p></td><td style="vertical-align:bottom"><p><strong>Placebo with Enzalutamide</strong></p><p><strong>N=84</strong></p></td><td style="vertical-align:bottom"><p><strong>TALZENNA with Enzalutamide</strong></p><p><strong>N=129</strong></p></td><td style="vertical-align:bottom"><p><strong>Placebo with Enzalutamide</strong></p><p><strong>N=115</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>rPFS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of events, n (%)</p></td><td style="vertical-align:top"><p>15 (21)</p></td><td style="vertical-align:top"><p>54 (64)</p></td><td style="vertical-align:top"><p>51 (40)</p></td><td style="vertical-align:top"><p>50 (43)</p></td></tr><tr><td style="vertical-align:top"><p>Median months (95% CI)</p></td><td style="vertical-align:top"><p>NE (NE, NE)</p></td><td style="vertical-align:top"><p>11.0 (8.3, 11.1)</p></td><td style="vertical-align:top"><p>24.7 (16.4, NE)</p></td><td style="vertical-align:top"><p>16.7 (13.8, 27.7)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.20 (0.11, 0.36)</p></td><td colspan="2" style="vertical-align:top"><p>0.72 (0.49, 1.07)</p></td></tr></tbody></table><p>Abbreviations: BRCAm=breast cancer susceptibility gene-mutated; CI=confidence interval; HRRm=homologous recombination repair gene‑mutated; NE=not evaluable; rPFS=radiographic progression-free survival.</p><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes 4 patients who were incorrectly randomized in the HRRm stratum who did not have HRR gene mutations.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with talazoparib in all subsets of the paediatric population in breast cancer (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Talazoparib exposure generally increased proportionally with dose across the range of 0.025&nbsp;mg to 2&nbsp;mg after daily administration of multiple doses. Following repeated daily dosing of 1&nbsp;mg talazoparib to patients, the geometric mean (% coefficient of variation [CV%]) area under the plasma concentration-time curve (AUC) and maximum observed plasma concentration (C<sub>max</sub>) of talazoparib at steady-state was in the range of 126&nbsp;(107)&nbsp;ng&bull;hr/mL to 208&nbsp;(37)&nbsp;ng&bull;hr/mL and 11 (90)&nbsp;ng/mL to 19&nbsp;(27)&nbsp;ng/mL, respectively. Following repeated daily dosing, plasma talazoparib concentrations reached steady-state within 2 to 3&nbsp;weeks. The median accumulation ratio of talazoparib following repeated oral administration of 1&nbsp;mg once daily was in the range of 2.3 to 5.2. Talazoparib is a substrate of P-gp and BCRP transporters.</p><p>&nbsp;</p><p>After administration of TALZENNA 0.5 mg orally once daily (the recommended dosage for prostate cancer) in combination with enzalutamide, the mean (CV%) steady-state Ctrough ranged from 3.29 to 3.68 ng/mL (45% to 48%).</p><p>Talazoparib plasma concentrations reached steady-state within 9 weeks when coadministered with enzalutamide.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>&nbsp;</p><p>Following oral administration of talazoparib, the median time to C<sub>max</sub> (T<sub>max</sub>) was generally between 1&nbsp;to 2&nbsp;hours after dosing. The absolute bioavailability study has not been conducted in humans. However, based on urinary excretion data the absolute bioavailability is at least 41% with fraction absorbed of at least 69% (see Elimination). No significant effect of acid-reducing agents on talazoparib exposure is expected, given sufficient solubility of talazoparib at all pHs between 1 and 6.8. Twenty-eight percent (28%) of the patients in the pivotal study were taking acid-reducing agents, mainly proton pump inhibitors.</p><p>&nbsp;</p><p><em>The effect of food</em></p><p>Food intake decreased the rate but not the extent of talazoparib absorption. Following a single oral dose of talazoparib with high-fat, high-calorie food (approximately 827 calories, 57% fat), the mean C<sub>max</sub> of talazoparib was decreased by approximately 46%, the median T<sub>max</sub> was delayed from 1 to 4&nbsp;hours, while the AUC<sub>inf</sub> was not affected. Based on these results, Talzenna can be administered with or without food (see section 4.2).</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>The population mean apparent volume of distribution (V<sub>ss</sub>/F) of talazoparib was 420 L. In vitro, talazoparib is approximately 74% bound to plasma proteins with no concentration dependence over the concentration range of 0.01&nbsp;&micro;M to 1&nbsp;&micro;M<strong>.</strong> Renal or hepatic impairment does not appear to impact talazoparib protein binding as there was no obvious trend in the mean talazoparib fraction of unbound drug (f<sub>u</sub>) in human plasma in vivo with worsening renal function or hepatic function.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Talazoparib undergoes minimal hepatic metabolism in humans. Following oral administration of a single 1&nbsp;mg dose of [<sup>14</sup>C]talazoparib to humans, no major circulating metabolites were identified in plasma, and talazoparib was the only circulating drug-derived entity identified. No metabolites that individually represented more than 10% of the administered dose were recovered in the urine or faeces.</p><p>&nbsp;</p><p><em>In vitro, </em>talazoparib was not an inhibitor of cytochrome (CYP)1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4/5 or inducer of CYP1A2, CYP2B6, or CYP3A4 at clinically relevant concentrations.</p><p>&nbsp;</p><p><em>In vitro</em>, talazoparib did not inhibit any of the major intestinal, hepatic or renal membrane transporters (P-gp, BCRP, organic anion transporting polypeptide [OATP]1B1, OATP1B3, organic cationic transporter [OCT]1, OCT2, organic anion transporter [OAT]1, OAT3, bile salt export pump [BSEP], multidrug and toxin extrusion [MATE]1 and MATE2-K) at clinically relevant concentrations.</p><p>&nbsp;</p><p><em>In vitro</em>, talazoparib did not inhibit any of the major uridine-diphosphate glucuronosyltransferase (UGT) isoforms (1A1, 1A4, 1A6, 1A9, 2B7, and 2B15) at clinically relevant concentrations.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Renal elimination of unchanged drug (passive filtration and active secretion) is the major route of talazoparib elimination. P-gp is likely involved in talazoparib active renal secretion. The mean (&plusmn;standard deviation) terminal plasma half-life of talazoparib was 90 (&plusmn;58)&nbsp;hours and the population mean (inter-subject variability) apparent oral clearance (CL/F) was 6.5 (31%)&nbsp;L/h in cancer patients. In 6&nbsp;female patients given a single oral dose of [<sup>14</sup>C]talazoparib, a mean of 69% (&plusmn;8.6%) and 20% (&plusmn;5.5%) of the total administered radioactive dose was recovered in urine and faeces, respectively. Excretion of unchanged talazoparib in urine was the major route of elimination accounting for 55% of the administered dose, while unchanged talazoparib recovered in the faeces accounted for 14%.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p>Age, sex, and body weight</p><p>&nbsp;</p><p>A population PK analysis was conducted using data from 490&nbsp;patients with cancer to evaluate the impact of age (ranging from 18 to 88&nbsp;years), sex (53&nbsp;males and 437&nbsp;females), and body weight (ranging from 35.7&nbsp;kg to 162&nbsp;kg) on the PK of talazoparib. The results have shown that age, sex, and body weight had no clinically relevant effect on the PK of talazoparib.</p><p>&nbsp;</p><p>Race</p><p><u>&nbsp;</u></p><p>Based on a population PK analysis that included 490 patients, where 41 patients were Asian and 449&nbsp;patients were Non-Asian (361&nbsp;White, 16&nbsp;Black, 9&nbsp;Others, and 63&nbsp;Not reported), talazoparib CL/F was higher in Asian patients compared to Non-Asian patients, leading to 19% lower exposure (AUC) in Asian patients.</p><p>&nbsp;</p><p>Paediatric population</p><p>&nbsp;</p><p>Pharmacokinetics of talazoparib have not been evaluated in patients &lt;&nbsp;18&nbsp;years of age.</p><p>&nbsp;</p><p>Renal impairment</p><p>&nbsp;</p><p>Data from a PK trial in advanced cancer patients with varying degrees of renal impairment indicated that talazoparib total exposure (AUC<sub>0-24</sub>) after multiple talazoparib once daily doses increased by 92% and 169% in patients with moderate (eGFR&nbsp;30&nbsp;&ndash;&nbsp;&lt;&nbsp;60&nbsp;mL/min) and severe (eGFR&nbsp;&lt;&nbsp;30&nbsp;mL/min) renal impairment, respectively, relative to patients with normal renal function (eGFR&nbsp;&ge;&nbsp;90&nbsp;mL/min). Talazoparib C<sub>max</sub> increased by 90% and 107% in patients with moderate and severe renal impairment, respectively, relative to patients with normal renal function. Talazoparib exposure was similar for patients with mild renal impairment (eGFR&nbsp;60&nbsp;&ndash;&nbsp;&lt;&nbsp;90&nbsp;mL/min) and those with normal renal function. In addition, based on a population PK analysis that included 490 patients, where 132 patients had mild renal impairment (60&nbsp;mL/min&nbsp;&le;&nbsp;CrCL&nbsp;&lt;&nbsp;90&nbsp;mL/min), 33 patients had moderate renal impairment (30&nbsp;mL/min&nbsp;&le;&nbsp;CrCL &lt;&nbsp;60 mL/min), and 1 patient had severe renal impairment (CrCL&nbsp;&lt;&nbsp;30&nbsp;mL/min),talazoparib CL/F was decreased by 14% and 37% in patients with mild and moderate renal impairment, corresponding to 17% and 59% increase in AUC, respectively, when compared to patients with normal renal function (CrCL&nbsp;&ge;&nbsp;90&nbsp;mL/min). The PK of talazoparib have not been studied in patients requiring haemodialysis (see section 4.2).</p><p>&nbsp;</p><p>Similar increases in AUC were observed with talazoparib when given in combination with enzalutamide for patients with moderate and severe renal impairment.</p><p>&nbsp;</p><p>Hepatic impairment</p><p>&nbsp;</p><p>Based on a population PK analysis that included 490 patients, where 118 patients had mild hepatic impairment (total bilirubin &le;&nbsp;1.0 &times; ULN and AST &gt;&nbsp;ULN, or total bilirubin &gt;&nbsp;1.0 to 1.5 &times; ULN and any AST), mild hepatic impairment had no effect on the PK of talazoparib. The PK of talazoparib in patients with normal hepatic function, mild hepatic impairment, moderate hepatic impairment (total bilirubin &gt;&nbsp;1.5 to 3.0 &times; ULN and any AST) or severe hepatic impairment (total bilirubin &gt;&nbsp;3.0 &times; ULN and any AST) was studied in a PK trial. Population PK analysis using data from this PK trial indicated that mild, moderate or severe hepatic impairment had no significant impact on the PK of talazoparib (see section 4.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Carcinogenicity</u></p><p>&nbsp;</p><p>Carcinogenicity studies have not been conducted with talazoparib.</p><p>&nbsp;</p><p><u>Genotoxicity</u></p><p>&nbsp;</p><p>Talazoparib was not mutagenic in a bacterial reverse mutation (Ames) test. Talazoparib was clastogenic in an <em>in vitro</em> chromosomal aberration assay in human peripheral blood lymphocytes and in an <em>in vivo</em> micronucleus assay in rats at exposures similar to clinically relevant doses. This clastogenicity is consistent with genomic instability resulting from the primary pharmacology of talazoparib, indicating the potential for genotoxicity in humans.</p><p>&nbsp;</p><p><u>Repeat-dose toxicity</u></p><p>&nbsp;</p><p>In repeat-dose toxicity studies in rats and in dogs, the main findings at subtherapeutic exposures included bone marrow hypocellularity with dose-dependent decrease in haematopoietic cells, depletion of lymphoid tissue in multiple organs and atrophy and/or degenerative changes in testes, epididymis and seminiferous tubules. Additional findings at higher exposures included dose-dependent increase in apoptosis/necrosis in the gastrointestinal (GI) tract, liver and ovary. Most of the histopathologic findings were generally reversible while the testes findings were partially reversible after 4 weeks of dosing cessation. These toxicity findings are consistent with the pharmacology of talazoparib and its tissue distribution pattern.</p><p>&nbsp;</p><p><u>Developmental toxicology</u></p><p>&nbsp;</p><p>In an embryo‑foetal development study in rats, talazoparib resulted in embryo‑foetal death, foetal malformation (depressed eye bulge, small eye, split sternebrae, fused cervical vertebral arch) and structural variations in bones at a maternal systemic AUC<sub>24</sub> exposure approximately 0.09-fold the relevant human exposure at the recommended dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsule content</u></p><p>&nbsp;</p><p>Silicified microcrystalline cellulose (sMCC) (microcrystalline cellulose and silicone dioxide)</p><p>&nbsp;</p><p><u>0.25&nbsp;mg capsule shell</u></p><p>&nbsp;</p><p>Hypromellose (HPMC)</p><p>Yellow iron Oxide (E172)</p><p>Titanium dioxide (E171)</p><p>&nbsp;</p><p><u>1&nbsp;mg capsule shell</u></p><p><em>&nbsp;</em></p><p>Hypromellose (HPMC)</p><p>Red iron oxide (E172)</p><p>Yellow iron oxide (E172)</p><p>Titanium dioxide (E171)</p><p>&nbsp;</p><p><u>Printing ink</u></p><p>&nbsp;</p><p>Shellac (E904)</p><p>Propylene glycol (E1520)</p><p>Ammonium hydroxide (E527)</p><p>Black iron oxide (E172)</p><p>Potassium hydroxide (E525)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>&nbsp;</p><p>After opening store TALZENNA below 30&deg;C and use it within 6 months.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Talzenna 0.1&nbsp;mg hard capsules</u></p><p>High-density polyethylene (HDPE) bottle and polypropylene (PP) closure with heat induction seal liner. Pack size: cartons of 30 capsules in a HDPE bottle.</p><p><u>&nbsp;</u></p><p><u>Talzenna 0.25&nbsp;mg hard capsules</u></p><p>High-density polyethylene (HDPE) bottle and polypropylene (PP) closure with heat induction seal liner. Pack size: cartons of 30 capsules in a HDPE bottle.</p><p>&nbsp;</p><p><u>Talzenna 0.35&nbsp;mg hard capsules</u></p><p>High-density polyethylene (HDPE) bottle and polypropylene (PP) closure with heat induction seal liner. Pack size: cartons of 30 capsules in a HDPE bottle.</p><p><u>&nbsp;</u></p><p><u>Talzenna 0.5&nbsp;mg hard capsules</u></p><p>High-density polyethylene (HDPE) bottle and polypropylene (PP) closure with heat induction seal liner. Pack size: cartons of 30 capsules in a HDPE bottle.</p><p>&nbsp;</p><p><u>Talzenna 1&nbsp;mg hard capsules</u></p><p>High-density polyethylene (HDPE) bottle and polypropylene (PP) closure with heat induction seal liner. Pack size: cartons of 30&nbsp;capsules in a HDPE bottle.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep this medicine out of the sight and reach of children.</p><p><em>&nbsp;</em></p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorisation Holder
Pfizer Inc., USA

Manufactured By
Excella GmbH & Co. KG
Nuernberger Str. 12, Feucht, Bavaria, Germany


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	EU: December 2021
	US: June 2023

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>